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ABSTRACT

Current approaches aimed at improving the efficacy of radiation as a cancer
treatment modality involve the development and application of molecularly targeted
radiosensitizers, a strategy that requires a thorough understanding of the fundamental
processes comprising the cellular radioresponse. Recent data indicating that radiation
modifies gene expression primarily through translational control rather than
transcriptional events suggests that mRNA translation contributes to cell survival after
irradiation. The overall goal of this project is to determine whether the regulatory/ratelimiting components of the translational machinery provide targets for tumor cell
radiosensitization. The majority of translation in mammalian cells occurs in a capdependent manner and is highly dependent on eIF4E.

As such, we investigated a

regulatory role for eIF4E in cellular radiosensitivity. eIF4E knockdown enhanced the
radiosensitivity of tumor but not normal cells. eIF4E knockdown inhibited the dispersal
of radiation-induced γH2AX foci. Furthermore, radiation was found to increase the
binding of >1000 unique mRNAs to eIF4E, many involved in DNA replication,
recombination, and repair. S6 kinase 1 (S6K1), also an important regulatory component
of the translational machinery, enhances the translation of specific mRNA
subpopulations, independent from eIF4E, and mediates ribosome biogenesis. The role of
S6K1 in determing cell survival after radiation was determined in several tumor cell lines
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and one normal cell line. S6K1 knockdown enhanced the radiosensitivity of all 3 tumor
lines. In contrast S6K1 knockdown had no effect on the cellular radiosensitivity of the
one normal line tested. The mechanistic target of rapamycin (mTOR) is a critical kinase
in the regulation of gene translation and has been suggested as a potential target for
radiosensitization. Importantly, it plays a major role in regulating eIF4E availability as
well as S6K1 activity. The radiosensitizing activities of the allosteric mTOR inhibitor
rapamycin with that of the ATP competitive mTOR inhibitor PP242 were compared.
Based on immunoblot analyses, whereas rapamycin only partially inhibited mTORC1
activity and had no effect on mTORC2, PP242 inhibited the activity of both mTOR
containing complexes. In the two tumor cell lines evaluated, PP242 treatment 1h before
irradiation increased radiosensitivity, whereas rapamycin had no effect. PP242 had no
effect on the cellular radiosensitivity of a normal lung fibroblast line. PP242 exposure
did not influence the initial level of γH2AX foci after irradiation, but did significantly
delay the dispersal of radiation-induced γH2AX foci. Finally, PP242 administration to
mice bearing U251 xenografts enhanced radiation-induced tumor growth delay. A next
generation analog of PP242, INK128, is currently undergoing analysis in clinical trials.
Given our data showing ATP-competitive mTOR inhibition is a strategy for tumor
radiosensitization as well as the fact that radiotherapy is a primary treatment modality for
locally advanced pancreatic ductal adenocarcinoma, the effects of INK128 on pancreatic
cancer radiosensitivity were determined. In three pancreatic cancer cell lines addition of
INK128 immediately after radiation resulted in radiosensitization. Consistent with the
effects of PP242 on other cell lines, INK128 exposure did not influence the initial level of
γH2AX foci after irradiation, but did significantly delay the dispersal of radiation-
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induced γH2AX foci. Furthermore, in pancreatic tumor xenografts INK128 inhibits
mTOR activity as well as cap-complex formation in a time-dependent manner. Lastly,
INK128 treatment significantly prolonged the radiation-induced tumor growth delay of
pancreatic tumor xenografts. In summary, the data provided in this thesis have begun to
characterize the role of the translational machinery in determining the cellular response to
radiation.
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CHAPTER 1:
Introduction
It is estimated in 2013 that there will be approximately 1.6 million non-skin
cancers diagnosed in North America (cancer.org), of which approximately 75% of these
patients will receive radiotherapy at sometime during their treatment course.

As

radiotherapy continues to be a primary treatment modality for the majority of patients
undergoing cancer therapy, the development of strategies to improve its efficacy could
benefit a large number of patients. This has led to an emphasis upon the development of
molecularly targeted radiosensitizers, a strategy that requires a thorough understanding of
the mechanisms mediating cellular radioresponse. Along these lines, radiation-induced
post-translational modifications of existing proteins (e.g. phosphorylation and
ubiquitination) have been the subject of extensive investigation. These modifications
have been linked causally to cellular radiosensitivity and play important roles in the DNA
damage response (DDR) and signal transduction pathways. As such, these modifications
have provided a rich source of potential targets for radiosensitization. Additionally, as
radiation has previously been shown to induce changes in the transcription of numerous
genes, the modulation of gene expression has also been thought to play a role in the
cellular radioresponse. That is, similar to prokaryotes radiation-induced changes in gene
expression in mammalian cells may constitute a protective or adaptive response against
radiation-induced cell death. As such, it has been generally thought that defining the
inducible genes as well as the mechanisms governing their expression may provide not
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only novel insight into the fundamental radioresponse, but may also lead to the
identification of targets for radiation sensitizers.
To examine the radiation-induced control of gene expression numerous studies
have published results of various analyses of total cellular mRNA (e.g. northern, RT-PCR
and microarray) in a number of normal cells and tissue as well as for tumor cell lines
grown both in vitro and in vivo (1-6). However, comparison of these changes in the
transcriptome reveals few commonly affected genes among the cell types evaluated or
even among tumor cell lines originating from tumors of identical histologic origin. In
addition, whereas these analyses accurately reflect changes in mRNA abundance, the
radiation-induced changes in mRNA levels do not correlate with changes in the
corresponding protein product. While there are exceptions involving individual genes
(2), the majority of radiation-induced changes in mRNA abundance have not been
extended to the protein level. Along these lines, Skanderová et al. directly compared
radiation-induced proteins with their corresponding mRNAs and reported no correlation
for the 10 proteins evaluated (7). As protein expression is the functional and operational
end product of gene expression, the lack of correlation between radiation-induced
changes in mRNA abundance and protein expression, as well as the established
heterogeneity among the cell lines, it is difficult to assign a functional consequence to
radiation-induced gene expression. Consistent with the aforementioned findings Birell et
al. showed that after irradiation of yeast, there was little to no relationship between
radiation radiation-induced transcriptional changes and survival after irradiation (8).
A fundamental assumption of these analyses is that radiation-induced changes in
gene expression are primarily the result of modifications in transcription. However, in
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addition to transcription, numerous post-transcriptional processes contribute to the
control of gene expression. In contrast to prokaryotic cells, mammalian transcription and
translation are not directly coupled, with each event confined to separate cellular
compartments (nucleus versus cytoplasm; Figure 1). Consistent with this uncoupling,
there is a poor correlation between changes in mRNA abundance and protein expression
in eukaryotic cells exposed to a number of types of stress (9-12). Furthermore even
under basal growth conditions the agreement between mRNA and protein expression
profiles was shown to be at best 65% in a study paneling the NCI-60 cell lines (13).
Accounting for the discrepancy between the transcriptome and the proteome is
translational control (14-16), which has been shown to play an important role in
regulating gene expression during such fundamental processes as embryogenesis (17), Tcell activation (18), growth factor signaling (19), and tumorigenesis (20).
More recent studies have begun to define the effects of radiation on translational
control (21-22). The initiation of translation involves the recruitment of mRNAs to
polyribosomes (polysomes), and as such the association of a given mRNA with
polysomes can then be used as an indicator of translational activity (15). To perform
global profiling of mRNAs undergoing translation (the translatome) these studies
employed microarray analysis of polysome-bound mRNA after radiation in a several cell
lines and these results were compared to radiation-induced changes in the transcriptome.
A study from our laboratory initially focused on the U87 glioma cell line and showed that
radiation affects ~10 fold more genes at the translational level than on the transcriptional
level (22). Furthermore, there was no overlap between genes affected translationally and
transcriptionally in U87 cells (22). Important with regards to functional consequence, a
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Figure 1: Post-transcriptional regulation and radiation.
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correlation between radiation-induced changes in polysome-bound mRNAs and changes
in the corresponding protein product was established, with 14/16 proteins evaluated
showing consistent changes in translational activity and protein expression (22). It was
then further shown that radiation-induced changes in translation were similar among 3
glioma cell lines, in contrast to radiation-induced changes in the transcriptome (22).
A second study published by our laboratory extended the results of the previously
mentioned study by profiling radiation-induced translational changes in a panel of 18 cell
lines, comprised of both tumor and normal cell lines (21). In contrast to changes in the
transcriptome, radiation-induced translational changes clustered according to the tissue of
origin (e.g. pancreatic carcinoma cell lines versus glioma cell lines). Network analyses
showed that the mRNAs affected at the translational level belonged to distinct functional
categories and were not a random collection of genes (21). Furthermore, many of these
functional categories appeared to histology-specific. Importantly, as the potential to
exploit differences in tumor and normal cells is of critical importance for therapeutic
application, many of the changes were exclusive to tumor or normal cells (21).
Consistent with our results another laboratory has recently published analysis of
polysome-bound mRNA and has shown radiation to affect the translation of numerous
mRNAs that are functionally related (23).

Although translational control of gene

expression appears to be a component of the cellular radioresponse, whether specific
molecules of the translational machinery are determinants of the cellular radiosensitivity
has yet to be determined, and is the subject of this thesis.
There are numerous processes involved in the post-transcriptional control of gene
expression (e.g. mRNA splicing, export, stability, and translation initiation) (24). Each of
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these processes can operate independently to regulate gene expression at the posttranscriptional level. RNA-binding proteins (RBPs), of which there are > 700 in humans,
play important roles in the regulation of each of the post-transcriptional processes (24).
Clearly, the mechanisms mediating the translational control of gene expression are
extremely complex with each step/event subject to regulation by environmental signals
including potentially radiation.

In fact, radiation has been shown to influence the

components of the post-transcriptional gene expression infrastructure as well as the
signaling pathways involved in their regulation (25-27). These processes, for the most
part, culminate in translation initiation and ribosome binding, the final and rate limiting
steps in mRNA translation (Figure 1) (28). Among the proteins regulating translation
initiation are eIF4E and S6K (29). Furthermore, the mechanistic target of rapamycin
(mTOR), which plays a major role in determining gene translation in response to
environmental and oncogenic stress, regulates the availability of eIF4E and activity of
S6K (29). Thus, to determine whether radiation-induced translation control of gene
expression influences radiosensitivity, these specific components of the translational
machinery were the focus of this thesis.
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CHAPTER 2:
Methods
Cell lines and treatments: MDA-MB-231 (breast adenocarcinoma), A549 (lung
adenocarcinoma) DU145 (prostate adenocarcinoma), and MRC9 (normal lung
fibroblasts) were obtained from American Type Culture Collection (ATCC).

U251

(glioma) cells were obtained from the Division of Cancer Treatment and Diagnosis
Tumor Repository (DCTD), National Cancer Institute (NCI). Miapaca-2, Panc1, and
PSN1 (all pancreatic cancer cell lines) were kind gifts from Dr. Deborah Citrin’s
laboratory. The cell lines were maintained in DMEM (MDA-MB-231 and U251), RPMI
(A549, Miapaca-2, Panc1, and PSN1), or MEM (DU145 and MRC9) media
supplemented with 10% FBS (Invitrogen, Carlsbad CA). ATCC employs short tandem
repeat DNA fingerprinting, karyotyping, and cytochrome C oxidase to authenticate cell
lines. Primary human mammary epithelial cells (HMEC) were obtained from GIBCO in
2010 and maintained in complete Mammary Epithelial Growth Medium (Lonza). All
cells were cultured less than 6 months after resuscitation. Cell cultures were maintained
in an atmosphere of 5% CO2/95% air at 37°C.

Ribavirin (Sigma-Aldrich), PP242

(Sigma-Aldrich or Chemdea) and rapamycin (EMD-Biochemicals) were dissolved in
dimethyl sulfoxide. Cell cultures were irradiated using a 320 X-ray source (Precision
XRay Inc.) at a dose rate of 2.3 Gy/min.
siRNA Transfection: A pool of four siRNA duplexes (SMARTpool) targeted to
eIF4E or S6K1 and a non-targeted siRNA pool (scramble) were purchased from
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Dharmacon Inc (Lafayette, CO).

Transfection with the respective siRNA pool was

carried out with cell cultures at 60-70% confluency using Dharmafect 1 transfection
reagent (Dharmacon) per manufacturer’s protocol. All experiments were carried out 72 h
post transfection.
Clonogenic Survival Assay: To evaluate radiosensitivity, cells were plated at
clonal density in 6-well plates, allowed to attach, followed by the specified drug and/or
radiation treatment protocol. 10 to 14 days after seeding, plates were stained with 0.5%
crystal violet, the number of colonies determined, and the surviving fractions were
calculated.

Radiation survival curves were generated after normalizing for the

cytotoxicity induced by eIF4E knockdown, S6K1 knockdown, rapamycin, PP242, or
INK128 treatment alone. Dose enhancement factor defined as the ratio of the dose of
radiation required to reduce surviving fraction to 0.1 in untreated cells to the dose of
radiation required to reduce surviving fraction to 0.1 in treated cells. Data presented are
the mean ± SEM from at least 3 independent experiments.
Immunoblotting and antibodies: Cells were lysed in 50mM Tris-HCl (pH 7.5),
150mM NaCl, 2mM EDTA, 2mM EGTA, 25mM NaF, 25mM β-glycerophosphate, 0.2%
Triton X-100, 0.3% NP-40, and 0.1mM sodium orthovanadate (for cytoplasmic proteins),
or 50mM Tris-HCL (ph 8.0), 1% SDS, and 10mM EDTA (for nuclear proteins);
supplemented with 1x phosphatase inhibitor cocktails II and III (Sigma-Aldrich), and 1x
HALT protease inhibitor cocktail (Thermo Scientific) for 15 minutes on ice. Total
protein was quantified using BCA protein assay (Thermo Scientific); separated by SDSPAGE; transferred to PVDF (Millipore) and probed with the indicated antibodies. Bands
were visualized using Pierce ECL Western Blotting Substrate (Thermo Scientific). Anti-
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eIF4E, anti-CHK1, anti-4E-BP-1, anti-phospho-eIF4E S209, anti-phospho-4E-BP-1
T37/46, anti-phospho-4E-BP-1 S65, anti-AKT, and anti-phospho-AKT s473 antibodies
were purchased from Cell Signaling Technology. Anti-β-actin and anti-eIF4G antibodies
were obtained from Sigma-Aldrich and BD Biosciences, respectively. Anti-Rad51 and
anti-Rad17 antibodies were purchased from Santa Cruz Biotechnologies. Donkey-antirabbit and sheep-anti-mouse Horseradish Peroxidase conjugated secondary antibodies
were purchased from GE Healthcare.
Cell Cycle Analysis: Cell cycle phase distribution was determined by flow
cytometric analysis. Cells were trypsinized, fixed with 70% ethanol, stained with Guava
Cell Cycle Reagent (Millipore), and analyzed with the Guava EasyCyte flow cytometer
(Millipore).
Apoptotic Cell Death: Cells undergoing apoptosis were quantified according to
annexin V staining (Annexin V Apoptosis Detection Kit, BD Biosciences). Briefly, for
each treatment condition cells were resuspended in 1x Annexin V Binding Buffer and
incubated with Annexin V-Cy5 antibody in the dark at room temperature. Hoechst 33258
was added for live/dead discrimination and samples analyzed by flow cytometry (BD
Biosciences LSRII flow cytometer).
Immunofluorescent analysis of γH2AX foci: To visualize foci, cells, grown in
chamber slides, were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton
X-100, and blocked with 1% bovine serum albumin (BSA) in PBS containing 5% goat
serum. The slides were incubated with antibody to phospho-H2AX (Millipore) followed
by incubation with goat-anti-mouse-Alexa488 (Invitrogen) and mounted with Prolong
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gold anti-fade reagent containing 4', 6-diamidino-2-phenylindole (Invitrogen) to visualize
nuclei. Cells were analyzed on a Zeiss upright fluorescent microscope.
Mitotic Catastrophe: Cells, grown in chamber slides, were fixed with a 10%
neutral buffered formalin solution and incubated with antibody to α-tubulin (SigmaAldrich) followed by incubation with goat anti-mouse with Alexa-488 antibody and
mounted with Prolong gold anti-fade reagent containing 4', 6-diamidino-2-phenylindole.
Cells with nuclear fragmentation, defined as the presence of two or more distinct nuclear
lobes within a single cell were classified as being in mitotic catastrophe.
Cap-Binding Assay: eIF4F cap complex formation was measured using m7-GTP
batch chromatography (30). Briefly, cells were lysed in 20mM Tris-HCl (pH 7.4),
150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM β-glycerophosphate, 1mM sodium
orthovanadate, 1% Triton X-100, 0.2mM PMSF, 1x phosphatase inhibitor cocktails II
and III (Sigma-Aldrich), and 1x HALT protease inhibitor cocktail (Thermo Scientific) for
15m on ice. 400µg of lysate were pre-cleared for 1h at 4°C then incubated with m7-GTP
Sepharose 4B beads (GE Healthcare) overnight at 4°C. Beads were washed three times
with lysis buffer; bound protein was eluted, denatured, and then separated using SDSPAGE followed by immunoblotting for eIF4G and eIF4E.
RIP-Chip and Microarray Analysis: The RIP-Chip kit and anti-eIF4E antibody
were obtained from MBL International (Woburn, Ma); the procedure was performed in
biological triplicate according to manufacturer’s protocol. Briefly, 107 cells were washed
followed by lysis and isolation of the cytoplasmic fraction, which was then pre-cleared
with Protein-A sepharose beads at 4°C for 1h. The lysates were then split into equal
parts; half was incubated with eIF4E conjugated Protein-A sepharose beads and half was
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incubated with IgG conjugated Protein-A sepharose beads (negative control). The RNA
associated with each type of bead was then eluted and isolated.
The isolated RNA was amplified using GeneChip 3’ IVT Express Kit
(Affymetrix) and hybridized to GeneChip Human genome U133A 2.0 array chips
(Affymetrix) per manufacturer’s protocol. Using Affymetrix Expression Console, Mas5
normalization was performed on all data sets. An expression cutoff of p < 0.05 was
implemented to filter all data.

The negative control expression values (IgG) were

subtracted from their respective sample counterparts on a probeset basis; the three
replicates were then averaged.

Probesets that had fold increase > 1.5 (radiation to

control) or went from an expression value less than or equal to 0 before radiation to
positive expression value after radiation (not bound to bound) were then further analyzed
by Ingenuity Pathway Analysis (IPA).

IPA curates a database that is defined by

interactions reported in the literature. Gene lists are uploaded to IPA and network
analysis was performed.

The IPA analysis was performed using the IPA database

available in October-December 2011. The data have been deposited in NCBI’s Gene
Expression Omnibus (31) and are accessible through GEO Series accession number
GSE36179.
In vivo Tumor Growth Delay: Eight to ten-week-old female athymic nude mice
(NCr nu/nu; NCI Animal Production Program, Frederick, MD) were used in these
studies. Animals are caged in groups of 5 or less and fed animal chow and water ad
libitum. A single cell suspension of U251 (107 cells), Miapaca-2 (5 x 106 cells), or PSN1
(5 x 106 cells) was injected subcutaneously into the right hind leg. When tumors grew to
a mean volume of approximately 210 mm3 (U251) or 180 mm3 (PSN1) mice were
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randomized into four groups: vehicle treated controls (5% N-Methylpyrrolidone, 15%
Polyvinylpyrrolidone, and 80% water), drug treated (PP242 or INK128), radiation (at
dose specified for specific experiment), or drug/radiation combination. The treatment
protocols are described in detail in the results sections of their respective chapters.
Radiation was delivered locally using a Pantak X Ray source with animals restrained in a
custom designed lead jig.

To obtain tumor growth curves, perpendicular diameter

measurements of each tumor were measured 2 to 3 times per week with a digital caliper
and volumes were calculated using a formula (L x W2) / 2. Data are expressed as mean ±
SEM tumor volume. Each experimental group contained between 5-7 mice. All animal
studies were conducted in accordance with the principles and procedures outlined in the
NIH Guide for Care and Use of Animals.
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CHAPTER 3:
Translation Initiation Factor eIF4E is a Target for Tumor Cell Radiosensitization

Note to Reader
Portions of the results have been previously published (Hayman TJ, Williams ES,
Jamal M, Shankavaram UT, Camphausen K, and Tofilon PJ (2012). Translation initiation
factor eIF4E is a target for tumor cell radiosensitization. Cancer Res 72, 2362-2372.) and
are utilized with permission of the publisher. Eli Williams helped design and complete
experiments; Muhammad Jamal helped with data acquisition; Uma Shankavaram assisted
with bioinformatics analysis; Kevin Camphausen and Philip Tofilon helped to design and
oversee project.
Abstract
A core component in the cellular response to radiation occurs at the level of
translational control of gene expression. Because a critical element in translation control
is the availability of the initiation factor eIF4E, which selectively enhances the capdependent translation of mRNAs, we investigated a regulatory role for eIF4E in cellular
radiosensitivity. eIF4E knockdown enhanced the radiosensitivity of tumor cell lines but
not normal cells. Similarly, pharmacological inhibition of eIF4E with ribavirin also
enhanced tumor cell radiosensitivity. In tumor cells eIF4E attenuation did not affect cell
cycle phase distribution or radiation-induced apoptosis, but it delayed the dispersion of
radiation-induced γH2AX foci and increased the frequency of radiation-induced mitotic
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catastrophe. Radiation did not affect 4E-BP1 phosphorylation or cap-complex formation
but it increased eIF4E binding to >1000 unique transcripts including many implicated in
DNA replication, recombination and repair. Taken together, our findings suggest that
eIF4E represents a logical therapeutic target to increase tumor cell radiosensitivity.
Introduction
In eukaryotic cells the majority of translation occurs in a cap-dependent manner,
which involves eIF4E binding to the 7-methyl guanosine (m7G) cap on the 5’ end of an
mRNA resulting in the recruitment of eIF4G and eIF4A to form the eIF4F initiation
complex and subsequently ribosome binding (32). This process is a final and ratelimiting step in translation initiation and is highly dependent on the availability of eIF4E.
Elevated levels of eIF4E preferentially enhance the translation of mRNAs with long,
highly structured 5’ untranslated regions (UTRs), which tend to encode proteins related
to cell proliferation and survival such as c-myc, Bcl2, FGF-2, and survivin (33-34).
Moreover, eIF4E also promotes the nucelocytoplasmic shuttling of select mRNAs such as
cyclin D and ornithine decarboxylase (ODC) with their increased cytoplasmic levels
leading to increased translation (33-34). Thus, via at least 2 mechanisms eIF4E plays a
critical role in the regulating gene translation.
At the cellular level elevated eIF4E has been implicated in oncogenesis (35).
Overexpression of eIF4E has been shown to drive the malignant transformation of
primary human mammary epithelial cells (36) and immortalized rodent cells (37) with
ectopic expression of eIF4E in animal models increasing the incidence of a variety of
tumor types (38). Evaluation of biopsy and surgical specimens indicates that eIF4E
expression is frequently elevated in a number of human cancers including breast,
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prostate, head and neck, and lung (33, 39). Increased eIF4E levels have also been
associated with malignant progression (40) as well as poor therapeutic outcome (41-42).
Finally, in preclinical models inhibition of eIF4E activity results in cytotoxicity for tumor
but not normal cells (42-43). Given eIF4E’s function in the translational control of gene
expression and data suggesting that it contributes to the neoplastic phenotype, we have
defined the consequences of eIF4E knockdown on the radiosensitivity of tumor and
normal cell lines. The data presented here indicate loss of eIF4E activity selectively
enhances tumor cell radiosensitivity through an inhibition of DNA double strand break
repair. In addition, radiation is shown to significantly increase the number of mRNAs
Results
To determine whether eIF4E plays a role in determining radiosensitivity 3 tumor
lines (MDA-MB-231, breast carcinoma; DU145, prostate carcinoma; A549, lung
carcinoma) and 2 normal cell lines (HMEC mammary epithelial and MRC9 lung
fibroblasts) were evaluated using the clonogenic survival assay. Each cell line was
treated with siRNA specific to eIF4E or non-targeted siRNA; 72h after transfection
cultures seeded at clonal density for survival analysis. As shown in Figure 2A, siRNA to
eIF4E reduced eIF4E protein levels significantly when compared to non-targeted siRNA.
The effects of eIF4E knockdown alone on the survival of each cell line are shown in
Figure 2B. eIF4E knockdown significantly reduced clonogenic survival of all three
tumor lines. As compared to the tumor cells, eIF4E knockdown induced significantly
less cytotoxicity in the normal cell lines. These results are consistent with previous
reports showing that tumor cells are more dependent on eIF4E for survival than normal
cells (43-44).
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The effects of eIF4E knockdown on cellular radiosensitivity are shown in Figure
3. For this study cells were treated as described above, trypsinized and irradiated 6h after
seeding. Treatment with siRNA to eIF4E resulted in an increase in the radiosensitivity of
each of the 3 tumor cell lines as compared to non-targeted siRNA (Figure 3A-C). The
dose enhancement factors at a surviving fraction of 0.1 (DEFs) for MDA-MB-231,
DU145, and A549 were 1.34, 1.24, and 1.44, respectively. The same experiment was
performed on the two normal cell lines (Figure 3D-E). In contrast to the tumor cell lines,
eIF4E knockdown had no effect on the radiosensitivity of the two normal cell lines.
These results suggest that eIF4E contributes to survival after irradiation of tumor but not
normal cells.
To investigate the mechanism responsible for the tumor cell radiosensitization
induced by eIF4E knockdown we focused on MDA-MB-231 cells. Given that eIF4E has
been reported to influence translation of a number of proteins involved in cell cycle
regulation (45), a reduction in eIF4E levels could result in cell cycle phase redistribution.
Because such an effect can be a critical factor in determining radiosensitivity, flow
cytometry was used to determine the cell cycle distribution in MDA-MB-231 cells after
eIF4E knockdown. As shown in Figure 4A the cell cycle phase distribution pattern was
not significantly altered at 72h after exposure to eIF4E siRNA as compared to nontargeted siRNA. These results indicated that redistribution of cells into a radiosensitive
phase of the cell cycle does not account for eIF4E knockdown-mediated enhancement in
radiation-induced cell killing. eIF4E knockdown has been shown to induce apoptosis in
breast cancer cell lines (46). To determine whether the increase in radiosensitivity
resulting from eIF4E knockdown was due to an enhancement of radiation-induced
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Figure 2: Effect of eIF4E knockdown on clonogenic cell survival. Cultures were
transfected with siRNA specific to eIF4E (eIF4E KD) or non-targeted siRNA (Scramble).
A) Representative immunoblots from each cell line showing extent of eIF4E protein
reduction 72h after transfection. B) 72h post-transfection cells were plated at specified
densities and colony-forming efficiency was determined 10-14 days later. Surviving
fractions for eIF4E KD cells were calculated after normalizing to the surviving fraction
obtained for cells receiving the scrambled siRNA. Values shown represent the means +
SE for 3-4 independent experiments. *p < 0.04 according to Student’s t test (all tumor
cell lines compared to HMEC).
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Figure 3: The effects of eIF4E knockdown on cellular radiosensitivity. A) MDA-MB231, B) A549, C) DU145, D) MRC9, and E) HMEC cells were transfected with nontargeted siRNA (Scramble) or siRNA specific for eIF4E (eIF4E KD). 72h posttransfection cells were plated, allowed to attach for 6h, and irradiated. Colony-forming
efficiency was determined 10-14 days later and survival curves were generated after
normalizing for cell killing from siRNA alone. DEFs were calculated at a surviving
fraction of 0.1. Values shown represent the mean + SE for 3-4 independent experiments.
* p < 0.05; ** p < 0.1 according to Student’s t test.

18

apoptosis, we determined Annexin V staining at 24 and 48h after exposure to 6 Gy for
cells exposed to siRNA to eIF4E and non-target siRNA. As expected for a solid tumor
cell line, radiation alone did not induce a significant apoptotic response, and this response
was not significantly enhanced with eIF4E knockdown (data not shown). These results
indicate that apoptosis is not the mechanism of cell death following radiation in eIF4E
deficient cells.
The critical lesion responsible for radiation-induced cell death is the DNA double
strand break (DSB). Because γH2AX foci correspond to radiation-induced DSBs and
their dispersal correlates with DSB repair (47-48), the effects of eIF4E knockdown on
radiation-induced γH2AX were evaluated in MDA-MB-231 cells (Figure 4B). At 1h
after exposure to 2 Gy no difference in foci levels was detected between control cells
(non-targeted siRNA) and cells in which eIF4E was knocked down, suggesting that
eIF4E levels have no effect on the initial level of radiation-induced DSBs. However, at 6
and 24h after irradiation (2 Gy) the number of γH2AX foci remaining in the eIF4E
knockdown cells was significantly greater than in control cells.

Additionally, a

significant level of γH2AX foci retention was observed in eIF4E deficient cells 24 h after
4 Gy when compared to non-targeted siRNA treated cells. These data suggest that eIF4E
knockdown results in an inhibition of radiation-induced DNA DSB repair.
Given the apparent inhibition of DSB repair and no increase in radiation-induced
apoptosis after eIF4E knockdown, we hypothesized that the mechanism of cell death
involved an increase in radiation-induced mitotic catastrophe.

Cells with nuclear

fragmentation, defined as the presence of two or more distinct nuclear lobes within a
single cell, were classified as being in mitotic catastrophe. As shown in Figure 4C, eIF4E
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Figure 4: Mechanism of radiosensitization by eIF4E knockdown. In the following
experiments MDA-MB-231 cells were transfected with siRNA specific to eIF4E (eIF4E
KD) or non-targeted siRNA (Scramble). All experiments were carried out 72 hours posttransfection. A) Cell cycle phase distribution was determined. Values represent the mean
of three independent experiments. B) Cells were irradiated with 2 or 4Gy and collected
at the specified time; γH2AX foci were counted in at least 50 cells per condition. Values
shown represent the means + SE for 3 independent experiments, *p < 0.04 according to
Student’s t test (eIF4E KD compared to scramble). C) Cells were irradiated (2 Gy) and
collected at the specified time points. Cells were classified as being in mitotic
catastrophe by the presence of nuclear fragmentation, which was defined as a single cell
containing two or more distinct nuclear lobes. At least 50 cells per condition were
scored. Values represent the mean + SE for 3 independent experiments. *p< 0.04
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knockdown resulted in a significant increase in the percentage of cells undergoing mitotic
catastrophe at 48 and 72h after exposure to 2 Gy. These results suggest the increase in
radiosensitivity following eIF4E knockdown involves the inhibition of DSB repair after
radiation, which then contributes to an increase in the number of cells undergoing mitotic
catastrophe.
A critical regulator of eIF4E is 4E-BP1, which binds to eIF4E preventing its
interaction

with

eIF4G

and

subsequently

eIF4F

complex

formation

(49).

Phosphorylation of 4E-BP1 releases eIF4E resulting in eIF4F formation and capdependent translation (28); it has been reported that exposure of normal human cell lines
to 8 Gy induces 4E-BP1 phosphorylation (25). However, exposure of MDA-MB-231
cells to 2 Gy under conditions used for clonogenic survival analysis (Figures 1-2) did not
increase 4E-BP phosphorylation (Figure 5A), with densitometry shown in Figure 5B.
Post-translational activation of eIF4E via phosphorylation at S209 has also been shown to
influence eIF4E activity (50); radiation had no effect on eIF4E phosphorylation (Figure
5A). m7-GTP batch chromatography is a standard approach for assessing eIF4F capcomplex formation (25, 30). Consistent with the lack of effect on 4E-BP1 and eIF4E
phosphorylation, radiation had no effect on cap-complex formation, as evidenced by the
lack of a change in bound eIF4G levels (Figure 5B). These results suggest that radiation
does not increase the overall activity of eIF4E or cap-dependent translation initiation in
general.
It is important to emphasize that eIF4E binding to a mRNA exists downstream of
a multitude of complex post-transcriptional changes of which many are subject to
regulation by radiation (as noted in Introduction). To further investigate the role of

21

Figure 5: The effect of radiation on eIF4E activation. A) MDA-MB-231 cells were
irradiated (2 Gy) and collected at the specified times and subjected to immunoblot
analysis. Actin was used as a loading control. B) Densitometric quantitation of
phosphor:total 4E-BP1 levels from immunoblot in Panel A. C) m7-GTP affinity
chromatography was performed on MDA-MB-231 cells that were irradiated and collected
1h after 2 Gy, and compared to unirradiated counterparts. m7-GTP bound and unbound
proteins (flow through) were resolved via SDS-PAGE followed by immunoblot analysis.
eIF4E was used as a loading control. Blots are representative of two independent
experiments.
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eIF4E in mediating these post-transcriptional changes induced by radiation, we
determined whether radiation influences the mRNAs bound to eIF4E using RIP-Chip
analysis (RNA-Binding protein immunoprecipitation followed by microarray analysis of
the bound mRNAs). In this experiment, MDA-MB-231 cells were irradiated (2 Gy), 6h
later cytoplasmic lysates were collected and eIF4E was immunoprecipitated. RNA was
then eluted from the immunoprecipitated eIF4E and subjected to microarray analysis,
which was compared to the same process performed on unirradiated cells.

In this

analysis irradiation was found to increase the eIF4E binding of 1124 unique transcripts
(either fold increase > 1.5 or not bound to bound as described in Materials in Methods).
The full list of genes is shown in Table A1 (Appendices). These transcripts were then
subjected to Ingenuity Pathway Analysis (IPA), which distributes genes into networks
defined by known interactions and then matches these networks with specific biologically
significant pathways. The top ten biological functions associated with the eIF4E bound
mRNAs are shown in Figure 6A. The specific functions of the genes contained within
the DNA Replication, Recombination, and Repair category are further delineated (Figure
6B) and shown to encompass many aspects of the DNA damage response, including DSB
repair and checkpoint control. To illustrate the interactions between the mRNA whose
binding to eIF4E was affected by radiation, the top ten networks and their associated
functions are shown in Table 1. Whereas there are numerous functions associated with
these networks, of particular interest with respect to radiosensitivity is Network 4 (Figure
6C), which includes genes associated with DNA Replication, Recombination and Repair.
Notably, this network contains several hub proteins: Rad17, Rad51, and CHEK1 each of
which influences several other proteins. Network 6, which involves genes participating
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A.

B.

Figure 6: Rip Chip analysis of the effects of radiation on eIF4E mRNA clients. MDA-MB-231 cells were irradiated
(2 Gy) and collected 6 hours later. eIF4E was immunoprecipitated, RNA bound to eIF4E was isolated and subjected to
microarray analysis and mRNAs whose binding to eIF4E after irradiation were classified using IPA. A) Left panel: top
ten biological functions (containing 100 or more genes) of the mRNAs whose binding to eIF4E was increased by
radiation; right panel: the biological functions of the mRNAs (with greater than 10 genes) within the DNA Replication,
Recombination, and Repair category are further delineated. B) Network 4 is shown with dark red indicating not bound
to bound and lighter red indicating fold increase > 1.5. C) Network 6 is shown with dark red indicating not bound to
bound and lighter red indicating fold increase > 1.5. D) Immunoblot analysis of DNA Damage Response related
proteins predicted by RIP-Chip analysis to be induced by radiation. MDA-MB-231 cells were irradiated (6 Gy) and
collected at the specified times. Actin was used as a loading control. Blots are representative of two independent
experiments.
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Table 1: Functions of mRNAs increasingly bound to eIF4E after irradiation	
  
Functions associated with the top ten networks for genes that were increasingly bound to eIF4E after radiation
(2Gy 6h) in MDA-MB-231 cells.
ID

Score

1

46

Focus
Molecules
33

2

44

33

Cancer, Cellular Movement, Connective Tissue Development and Function

3
4

44
42

32
31

Cancer, Infectious Disease, Respiratory Disease
DNA Replication, Recombination, and Repair, Cell Cycle, Gene Expression

5

39

30

6

39

30

7
8

37
35

29
28

9
10

33
32

27
27

Cellular Function and Maintenance, Cellular Compromise, Tissue
Development
RNA Post-Transcriptional Modification, Dermatological Diseases and
Conditions, Genetic Disorder
Post-Translational Modification, Cellular Movement, Cell Cycle
Amino Acid Metabolism, Small Molecule Biochemistry, Cellular Assembly
and Organization
Post-Translational Modification, Protein Degradation, Protein Synthesis
Endocrine System Development and Function, Lipid Metabolism, Molecular
Transport

Top Functions
Genetic Disorder, Skeletal and Muscular Disorders, Neurological Disease
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in RNA post-transcriptional processing is shown in Figure 6D; it also includes several
hub proteins (e.g., ELAVL1, snRNP, and PRPF4). This network illustrates eIF4E’s
capacity to modulate the post-transcriptional regulation of gene expression both
directly,as an RNA Binding Protein (RBP), and indirectly through its influence on other
proteins involved in post-transcriptional mRNA processing. The data presented in Figure
6 indicate that genes targeted by eIF4E after irradiation are not a random collection, but
instead are functionally related mRNA subsets.
Given eIF4E’s role in cap-dependent translation, an increase in the binding of a
given mRNA to eIF4E would be expected to result in an increase in its corresponding
protein product. Thus, to investigate the functional significance of the RIP-Chip analysis,
we determined the effects of radiation on the levels of three of the hub proteins from
Network 4 (CHK1, Rad17, and Rad51), proteins with established roles in the DNA
damage response (51-53). MDA-MB-231 cells were irradiated (6 Gy) and collected for
protein analysis at times out to 24h. As shown in Figure 6E, the levels of CHK1, Rad17,
and Rad51 were increased after irradiation, consistent with a correlation between the
mRNAs whose binding to eIF4E was increased after irradiation and the increase in their
corresponding protein.
Because the data presented above suggest that eIF4E may serve as a target for
radiosensitization, we determined the effects of ribavirin on the radiosensitivity of MDAMD-231 cells. Whereas initially described as an anti-viral therapy, recent laboratory
studies have shown that ribavirin inhibits eIF4E activity (44, 54) providing a basis for
clinical trials as an anti-neoplastic treatment. To test whether pharmacological inhibition
of eIF4E results in similar radiosensitization to eIF4E knockdown, MDA-MB-231 cells
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Figure 7: Effects of ribavirin on radiosensitivity. MDA-MB-231 cells were plated for
clonogenic survival analysis and treated with 50 µM ribavirin for 1h, followed by
radiation. Ribavirin was left on for the duration of the clonogenic assay. Values represent
the

mean

+

SE

for

3
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independent

experiments.

were plated for clonogenic survival analysis, treated with 50 µM ribavirin, a
concentration that inhibits eIF4E activity in breast cancer cells (42), for 1h and irradiated.
Ribavirin treatment alone reduced the surviving fraction to 0.30 + 0.07, similar to that
induced by eIF4E knockdown. As shown in Figure 7 this ribavirin treatment protocol
enhanced the radiosensitivity of MDA-MB-231 cells with a DEF of 1.35. These results
suggest that targeting eIF4E may be a valid strategy for radiosensitization.
Discussion
Based on γH2AX data, the mechanism through which eIF4E influences tumor cell
radiosensitivity appears to involve DNA DSB repair. It is unlikely that this translation
initiation factor directly participates in the DSB repair process suggesting that the
mechanism involves an aspect of the post-transcriptional regulation of gene expression.
We have previously shown that radiation affects the translation of certain subsets of
mRNAs through recruitment of existing mRNAs to and away from polysomes (21-22).
The RIP-Chip results presented here showing that radiation enhances the binding of
eIF4E to specific mRNA subpopulations is consistent with the radiation-induced
translational control of gene expression. Moreover, a major subset of the mRNAs whose
eIF4E binding was increased by radiation corresponded to those coding for proteins
involved in DNA Replication, Recombination and Repair and Cell Cycle, which could
then play a role in determining radiosensitivity.

A role for radiation-induced gene

translation in the cell survival response is suggested by the recent work by Singh et.al.
showing that DNA DSBs are generated not only from the initial radiation deposition, but
also from chemical processing occurring for hours after exposure to radiation (55). In
this situation a requirement for the rapid increase in DNA repair proteins may contribute
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to the recovery process. However, based on the experiments using siRNA to knockdown
eIF4E (Figure 3), it is not possible to determine whether the tumor cell radiosensitization
was the result of eliminating the radiation-induced enhancement in gene translation
and/or changes in mRNA translation that are induced before irradiation. Along these
lines, the eIF4E inhibitor ribavirin enhanced MDA-MD-231 cells radiosensitivity when
given 1h before irradiation (Figure 7). Clearly, the mechanisms through which the
reduction of eIF4E levels affect radiation-induced tumor cell killing require additional
investigation.
Whereas knockdown of eIF4E levels induced radiosensitization of tumor cells,
the same procedure had no effect on the radiosensitivity of normal cell lines. This tumor
selectivity may involve the increased dependence of tumor cells on eIF4E activity. For
both ribavirin and an antisense oligonucleotide (ASO) to eIF4E, tumor cells are more
sensitive in terms of cytoxicity than normal cells. (42-43) Consistent with these previous
findings knockdown of eIF4E in the current study reduced survival of the tumor cell lines
to a greater degree than on the normal cells. eIF4E serves as a funnel point (56) for a
number of oncogenic pathways reflecting the consequences of activation of RTKs along
with Ras and PI3K pathways (34, 57-58). The elevated eIF4E availability under these
circumstances then putatively enhances the translation selectively and disproportionally
of genes mediating cell proliferation and survival and other processes contributing to the
neoplastic phenotype (59). It would seem that many of the eIF4E dependent genes whose
translation is increased in tumor cells may also contribute to the ability of the cell to
survive after a variety of insults including radiation.
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Whereas the mechanisms remain to be completely defined, in the study described
here knockdown of eIF4E was shown to enhance the radiosensitivty of 3 human tumor
lines while having no effect on the radiosensitivity of 2 normal cell lines. These data
suggest that eIF4E provides a tumor selective target for radiosensitization. Because
laboratory data has already indicated that eIF4E contributes to the neoplastic phenotype,
strategies for targeting eIF4E are being investigated at the preclinical and clinical setting.
One approach is the use of an ATP-active site inhibitor of mTOR.

In contrast to

allosteric mTOR inhibitors, i.e. rapalogs, the active site inhibitors completely inhibit
mTORC1 function, preventing the phosphorylation of the mTOR substrate 4E-BP1,
which prevents release of eIF4E and limits its availability for eIF4F formation (60). An
additional approach has been the development of small molecule inhibitors of the eIF4EeIF4G interaction, which prevent complete formation of the eIF4F cap-complex (61).
Inhibiting eIF4E expression with an eIF4E ASO has been shown to reduce eIF4E levels
and to inhibit tumor cell growth in preclinical models (43). Finally, there has been
considerable pre-clinical data evaluating ribavirin as an eIF4E activity inhibitor (44, 54).
The mTOR active site inhibitors, ribavirin, and the eIF4E ASO are currently in clinical
trials both as single agents (59, 62-63), as well as in combination with chemotherapy
(64). The data presented in the current study showing that reduced eIF4E expression
selectively enhances tumor radiosensitivity supports the clinical evaluation of these
eIF4E-targeting strategies in combination with radiotherapy.
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CHAPTER 4:
Ribosomal Protein S6 Kinase 1 as a Determinant of Cellular Radiosensitivity
Abstract
The ribosomal protein S6 kinases (S6Ks) are downstream effectors of the mTOR
kinase and regulate a wide variety of cellular processes including translation initiation,
ribosome biogenesis, and cell growth. Furthermore, the S6Ks are activated in a variety of
malignancies and are associated with an enhancement of the malignant phenotype. To
determine the role of S6K1 in regulating intrinsic cellular radiosensitivity, a panel of 3
tumor cell lines initiated tumors of different histologic origin and one normal cell line
were treated with siRNA to S6K1. S6K1 knockdown enhanced the radiosensitivity of all
3 tumor lines as determined by clonogenic survival analysis.

In contrast, S6K1

knockdown had no effect on the cellular radiosensitivity of the normal lung fibroblast
line, MRC9. S6K1 knockdown increased expression of PDCD4, a tumor suppressor
implicated in the cellular DNA damage response. Taken together these results suggest
S6K1 is a potential tumor specific target for the enhancement of cellular radiosensitivity,
and that its effects may be in part mediated by increased expression of PDCD4.
Introduction
As described in Chapter 2 we have shown that eIF4E, a critical and rate-limiting
component of the translational machinery determines tumor cell radiosensitivity, and
plays an integral role in the translational response to radiation. In addition to eIF4E, the
p70 ribosomal protein S6 kinases (S6Ks) have a critical role in the regulation of mRNA
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translation (65). There are two distinct genes encoding the p70 S6Ks (S6K1 and S6K2)
(49). Most work characterizing these proteins has been done with S6K1, whereas there is
less known about the function of S6K2 (49). S6K1 is a downstream effector of mTORC1
and regulate a wide variety of cellular processes including translation initiation, ribosome
biogenesis, lipid synthesis, de novo pyrimidine synthesis, and cell growth (66). It exerts
control over the translational machinery at multiple levels. The first identified substrate
of S6K1 was ribosomal protein S6 (rpS6) a component of the 40S ribosome subunit that
positively regulates translation and protein synthesis (66). There is conflicting evidence
that S6K1 selectively regulates the translation of mRNAs containing 5’ TOP (terminal
oligopyrimidine) tracts (67-68). These mRNAs typically encode ribosomal proteins and
translation factors (69). S6K1 also controls levels of the tumor suppressor, PDCD4
(programmed cell death 4) (70), a negative regulator of translation that inhibits the
translation initiation factor eIF4A (71), a RNA helicase that is a component of the eIF4F
cap-complex. eIF4A helicase activity is important for the unwinding of 5’ UTRs that are
highly structured (65). PDCD4 phosphorylation by S6K is followed by ubiquitylation via
the ubiquitin	
   ligase	
   SCF-‐β-‐TRCP, and proteosomal degradation (70). Degradation of
PDCD4 causes the release of eIF4A from PDCD4 and allows eIF4A to associate with the
eIF4F cap-complex (70).

Importantly, in the context of our study, PDCD4 has been

linked to the cellular DNA damage response (72-73). In particular, PDCD4 knockdown
of the human tumor cell line, HeLA, has been shown to decrease sensitivity to UV
irradiation (74).

Additionally, S6K enhances translation via phosphorylation of the

initiation factor eIF4B. eIF4B phosphorylation by S6K1 enhances the helicase activity of
eIF4A (65). This activation of eIF4B has been shown to correlate with its ability to
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promote the translation of mRNAs with long and structured 5’ UTRs (29). Lastly, S6K1
phosphorylates and inactivates the repressor of translation elongation eEF2K (eukaryotic
elongation factor 2 kinase). eEF2K functions to phosphorylate and inhibit eEF2, a
protein that mediates the translocation step of translation elongation (75).
S6K is activated, either through phosphorylation, or overexpression in a wide
variety of malignancies and has been associated with poor prognosis in breast cancer (66)
and gliomas (76). Activation in breast (77), colon (78), and liver tumors (79) was
associated with a more malignant phenotype.

S6K has been associated with glial

transformation (80). Additionally, in several breast cancer cell lines, S6K has been
associated with regulating cell survival (81). Activation of the mTOR/S6K pathway has
also been associated with resistance to traditional chemotherapies (e.g. cisplatin) (66).
Several factors (EGF, HGF, and SCF) and cytokines signal through S6K to partially exert
their oncogenic activity (66).

As such there has been considerable interest in the

development of agents targeting S6K, with several in clinical trials: LY2584702 and
XL418 (66). As radiation influences the translation of specific subsets of mRNAs, and
S6K1 regulates translation, we addressed on the role of S6K1 in the cellular
radioresponse in both tumor and normal cells.

Reduction of S6K1 levels via siRNA

knockdown enhanced the radiosensitivity of 3 tumor lines but not of normal lung
fibroblasts. Furthermore, consistent with previous literature, S6K1 knockdown induced
the expression of PDCD4 in A549 cells. These data provide initial insight into the role
of S6K1 in regulating the cellular radioresponse as well as provide the basis for further
studies investigating the application of S6K inhibitors with radiotherapy.
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Results
To test the hypothesis that S6 kinase plays a role in determining cellular
radiosensitivity we employed a siRNA mediated approach to reduce S6K1 levels. Using
3 tumor lines originated from tumors of distinct histologies (A549 lung adenocarcinoma,
MDA-MB-231 breast carcinoma, and Panc1 pancreatic adenocarcinoma) and 1 normal
cell line (MRC9 lung fibroblasts) the effects of S6K1 knockdown on cellular
radiosensitivity were evaluated with the clonogenic survival assay. Each cell line was
treated with siRNA specific to S6K1 (S6K KD) or non-targeted siRNA (scramble); 72h
after transfection cultures were trypsinized to generated a single cell suspension and
seeded at clonal density for survival analysis. The effects of S6K1 knockdown on cell
survival were determined. As shown in Figure 8A, siRNA to S6K1 reduced S6K1
protein levels significantly when compared to non-targeted siRNA. Treatment with
S6K1 siRNA reduced the surviving fraction to 0.77 ± 0.03, 0.68 ± .10, 0.30 ± .01, and
0.11 ± 0.05 in A549, MDA-MB-231, Panc1, and MRC9 cells respectively. These data
indicate that in vitro S6K knockdown does not have a consistent cytotoxic effect with
respect to tumor versus normal cells.
The effects of S6K1 knockdown on cellular radiosensitivity are shown in Figure
8. For this study cells were treated as described above, and irradiated 6h after seeding.
Treatment with siRNA to S6K1 resulted in an increase in the radiosensitivity of each of
the 3 tumor cell lines as compared to non-targeted siRNA (Figure 8B-D). The dose
enhancement factors at a surviving fraction of 0.1 (DEFs) for A549, MDA-MB-231, and
Panc1 were 1.35, 1.42, and 1.44, respectively. The same experiment was performed on
the normal lung fibroblast cell line (Figure 8E). In contrast to the tumor cell lines, S6K1
knockdown had no effect on the radiosensitivity of the normal cell line, MRC9. These
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Figure 8: The effects of S6K1 knockdown on cellular radiosensitivity. Cells were
transfected with siRNA to S6K1 (S6K KD) or non-targeted siRNA (Scramble). A,
immunoblots from each cell line showing extent of S6K protein reduction 72 hours after
transfection. A549 (B), MDA-MB-231 (C), Panc1 (D), and MRC9 (E), cells were plated
seventy-two hours posttransfection, allowed to attach for 6 hours, and irradiated.
Colony-forming efficiency was determined 10 to 14 days later, and survival curves were
generated after normalizing for cell killing from siRNA alone. DEFS were calculated at
a surviving fraction of 0.1.
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Figure 9: The effects of S6K1 knockdown on PDCD4 expression. A) Immunoblot
analysis 6K1 and PDCD4 expression in untreated cells (control) or cells transfected with
siRNA to S6K1 (S6K KD) or non-targeted siRNA (Scramble). Actin was used as a
loading control.
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results suggest that S6K1 contributes to survival after irradiation of tumor but not normal
cells.
As described in the Introduction the expression of the tumor suppressor PDCD4
has been shown to be controlled by S6K (70). To determine whether S6K knockdown
results in increased expression of PDCD4 in the cell lines studied immunoblot analysis of
A549 and Panc1 cells treated with siRNA to S6K or non-targeted siRNA was performed.
The results of this analysis are shown in Figure 9. In both cell lines PDCD4 expression
was increased upon treatment with siRNA specific to S6K relative to the non-targeted
siRNA control, consistent with previous reports.
Discussion
Whereas the mechanism of radiosensitization remains to be defined, in the study
presented here knockdown of S6K1 was shown to increase the radiosensitivity of 3 tumor
lines initiated from tumors of different histologies. In contrast to the 3 tumor cell lines
tested, S6K knockdown had no effect on the cellular radiosensitivity of the normal lung
fibroblast line MRC9. In order to make a definitive conclusion about the possible tumor
specificity of S6K1 as a target for enhancing radiosensitivity, these results should be
extended to other normal cell lines. However, our initial investigations suggest that
S6K1 appears to be a potential tumor selective target. Whereas we have not defined the
exact mechanisms regarding this potential tumor selectivity, there are numerous studies,
both pre-clinically and clinically, showing over-expression and hyperactivation of S6K in
tumor versus normal tissue (66, 76-79). Furthermore, as described in the Introduction,
S6K is controlled primarily by mTORC1. Numerous genetic alterations and upstream
signaling events (e.g. Ras mutations and PI3K/AKT activation) that affect mTORC1
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signaling have been reported in the context of oncogenesis and tumor progression (82).
Additionally, S6K plays an important regulatory role in the control of mRNA translation
(49). Data from our laboratory have shown radiation to control gene expression primarily
through regulation of gene translation (21-22). These experiments also examined the
translational response to radiation in tumor versus normal cells (21). Importantly tumor
cells and normal cells had strikingly different translational responses to ionizing radiation
exposure (21). It is possible to speculate that this potential tumor selective enhancement
in radiosensitization seen with S6K1 knockdown is due to the aforementioned differences
in S6K regulation and activity. Determining the differences responsible for this potential
tumor selectivity in the context of S6K1 as a target for radiosensitization will be the
subject for future investigation.
In the context of DNA damage, PDCD4 has been shown to play a role in
determining cell survival after exposure to DNA damage.

Specifically, PDCD4

knockdown of HeLa cells has been shown to increase survival to ultraviolet radiation
(74). This affect was attributed to PDCD4’s ability to suppress the translation of p53
responsive genes, such as p21 and GADD45a (74). While work remains to be done in
establishing a causal role of PDCD4 in mediating S6K1 knockdown-induced
radiosensitization, our results are in general agreement with this study as we show that
S6K knockdown increases PDCD4 expression and decreases cell survival after exposure
to ionizing radiation.
In addition, as described in the introduction, S6K1 plays an important role in the
regulation of cap-dependent translation through its control of eIF4A. eIF4A has been
shown to selectively control the translation of oncogenic transcripts (83). Silvestrol, a
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naturally occurring compound, has been reported to inhibit the activity of eIF4A and
suppress translation of specific subsets of oncogenic mRNAs (84).

Furthermore,

combination of silvestrol with the DNA damaging agent doxorubicin showed a
synergistic effect in extending survival (85). This combination therapy with silvestrol
and doxorubicin was only synergistic in mice that harbored activation of the mTOR
pathway. Additionally, there is data in inflammatory breast cancer cells showing that
eIF4A knockdown or pharmacologic inhibition results in radiosensitization (86). Given
these reports as well as our data showing an increase in PDCD4, a repressor of eIF4A
activity, it is possible to conclude that S6K1 knockdown’s influence on radiosensitivity
may be in part due to effects of increased PDCD4 expression on eIF4A activity.
Additionally, given the data showing eIF4A inhibition synergizes with DNA damage
only in the context of hyperactive PI3K/mTOR signaling (85) and the established
activation of PI3K/mTOR signaling observed in tumor cells, it is possible that this is the
mechanism for the potential tumor specific radiosensitization observed. In conclusion,
these data suggest that targeting S6K is a potential target for tumor selective
radiosensitization; however, the mechanisms underlying this effect largely remain
undetermined and will be the subject of future investigation.
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CHAPTER 5:
Allosteric versus ATP-Competitive mTOR Inhibition and Radiosensitivity

Note to Reader
Portions of the results have been previously published (Hayman	
   TJ	
   Kramp	
   T,	
  
Kahn	
   J,	
   Jamal	
   M,	
   Camphausen	
   K,	
   Tofilon	
   PJ.	
   Competitive	
   but	
   not	
   allosteric	
   mTOR	
  
kinase	
   inhibition	
   enhances	
   tumor	
   cell	
   radiosensitivity.	
   Translational	
   Oncology.	
  
2013;	
  in	
  press.) and are utilized with permission of the publisher. Tamalee Kramp and
Muhammad Jamal assisted with animal experiments; Jenna Kahn assisted with in vitro
data acquisition; Kevin Camphausen and Philip Tofilon helped to design and oversee
project.
Abstract
The mechanistic target of rapamycin (mTOR) is a critical kinase in the regulation
of gene translation and has been suggested as a potential target for radiosensitization.
The goal of this study was to compare the radiosensitizing activities of the allosteric
mTOR inhibitor rapamycin with that of the ATP competitive mTOR inhibitor PP242.
Based on immunoblot analyses, whereas rapamycin only partially inhibited mTORC1
activity and had no effect on mTORC2, PP242 inhibited the activity of both mTOR
containing complexes. Irradiation alone had no effect on mTORC1 or mTORC2 activity.
Clonogenic survival was used to define the effects of the mTOR inhibitors on in vitro
radiosensitivity.

In the two tumor cell lines evaluated, PP242 treatment 1h before
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irradiation increased radiosensitivity, whereas rapamycin had no effect. Addition of
PP242 to culture media immediately, 1, or 6h after irradiation also enhanced the
radiosensitivity of both tumor lines. To investigate the mechanism of radiosensitization,
the induction and repair of DNA double strand breaks were evaluated according to
γH2AX foci. PP242 exposure did not influence the initial level of γH2AX foci after
irradiation, but did significantly delay the dispersal of radiation-induced γH2AX foci. In
contrast to the tumor cell lines, the radiosensitivity of a normal human fibroblast cell line
was not influenced by PP242. Finally, PP242 administration to mice bearing U251
xenografts enhanced radiation-induced tumor growth delay. These results indicate that in
a preclinical tumor model PP242 enhances tumor cell radiosensitivity both in vitro and in
vivo and suggest this effect involves an inhibition of DNA repair.
Introduction
A primary determinant of eIF4E activity is the mechanistic target of rapamycin
(mTOR), which plays a critical role in regulating mRNA translation and protein synthesis
in response to a variety of environmental signals (82). mTOR exists in two distinct
complexes: mTOR complex 1 (mTORC1), which includes Raptor, Pras40, Deptor, and
Mlst8, and mTOR complex 2 (mTORC2), which includes Rictor, mSin1, Protor1/2 and
Mlst8 (82). The major substrates for mTORC1 kinase activity are eIF4E-binding protein
1 (4E-BP1), and the ribosomal protein s6 kinase 1 (S6K1). In the hypophosphorylated
state, 4E-BP binds to eIF4E preventing its association with eIF4G, the formation of the
eIF4F complex, and cap-dependent translation (28).

However, when 4E-BP1 is

phosphorylated by mTORC1 it is released from eIF4E and the eIF4F cap-complex is
assembled. The substrates of mTORC2 are less well defined, but include AGC kinases
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such as AKT, SGK, and PKC (65). Of note, mTORC2 phosphorylation of AKT at s473
can indirectly lead to enhancement mTORC1 activation (87-88).
mTOR is a major downstream effector of a number of signaling pathways (e.g.
PI3K/AKT, RAS/MAPK, and RTKs) (56, 82). Because these pathways are frequently
activated or dysregulated in tumors, mTOR has been considered a target for cancer
therapy (89). Most studies of mTOR have focused on the use of the allosteric inhibitor
rapamycin and its analogs (rapalogs), which incompletely inhibit mTORC1 output and do
not inhibit mTORC2 (90). In the context of cancer treatment, these drugs have shown
modest activity with respect to patient outcomes (59). The resistance of some tumors to
rapalogs as single agents has been attributed to their incomplete inhibition of 4E-BP1
phosphorylation, feedback activation of AKT, and/or the lack of mTORC2 inhibition (9091). In contrast to the allosteric inhibitors, more recently developed ATP-competitive
inhibitors of mTOR inhibit mTORC1 output more completely and inhibit mTORC2,
which prevents the feedback activation of AKT following S6K inhibition (87, 92-95).
Given mTOR’s role in regulating eIF4E activity, we have defined the consequences of an
allosteric (rapamycin) and ATP-competitive (PP242) mTOR inhibitor on the
radiosensitivity of tumor and normal cells. The data presented here indicate that the
mTORC1/2 inhibition achieved using the ATP-competitive inhibitor PP242 enhances
tumor cell radiosensitivity in vitro and in vivo and suggest that this effect involves an
inhibition of DNA double-strand break (DSB) repair.
Results
To investigate the effects of rapamycin and PP242 on tumor cell radiosensitivity,
two human cell lines initiated from solid tumors were used: MDA-MB-231 (breast
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carcinoma) and U251 (glioma).

Initially, mTORC1 and mTORC2 activity was

determined in each cell line after a 1h exposure to PP242 or rapamycin (Figures 10A and
B). The goal of this analysis was not only to compare drugs with respect to inhibitory
activity but to also define the minimal concentration of each drug necessary to elicit the
maximally achievable mTOR kinase inhibition. Towards this end, the levels of p-S6K
(t389) and p-4E-BP1 (t37/46 and s65) were used as readouts for mTORC1 activity; pAKT (s473) was used as a marker for mTORC2 activity. Rapamycin exposure reduced
p-S6K and marginally reduced p-4E-BP1 levels in both cell lines with essentially the
same reductions induced by 5 and 10nM. No further reductions in these indicators of
mTORC1 activity were achieved by increasing rapamycin concentrations out to 500 nM
(data not shown), consistent with previous reports (59, 96). PP242 exposure (1 and 2
µmol/L) reduced p-S6k levels to a similar degree as rapamycin. However, PP242 was
considerably more effective at reducing the levels of p-4E-BP1 than rapamycin, as
previously shown (92-93). In contrast to rapamycin, PP242 inhibited the phosphorylation
of AKT at s473 in both tumor cell lines, indicative of an inhibition of mTORC2 activity.
Thus, as reported for other cell lines (92-93), in U251 and MDA-MB-231 cells PP242
inhibits the rapamycin resistant functions of mTOR.
To determine whether irradiation influences mTOR activity, U251 and MDAMB-231 cells were exposed to 2 Gy and collected for immunoblot analysis at times out to
6h (Figures 11A and B). Based on levels of p-AKT, p-S6K, and p-4E-BP1, radiation did
not increase mTORC1 or mTORC2 activity in either of these tumor cell lines. These
measures were conducted using cells grown under optimal in vitro conditions (i.e. 10%
FBS) applicable to clonogenic survival analysis. Whereas previous reports showed that
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Figure 10: Effects of rapamycin and PP242 on mTORC1/2 activity. A) U251 and B)
MDA-MB-231 cells were treated for 1h with the specified dose of inhibitor. Cells were
collected and subjected to immunoblot analysis. Actin was used as a loading control.
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Figure 11: The effect of radiation on mTOR activity. A) U251 and B) MDA-MB-231
cells were irradiated (2 Gy) and collected at the specified times and subjected to
immunoblot analysis. Actin was used as a loading control. Immunoblots are
representative of two independent experiments.
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radiation increased mTORC1 and mTORC2 activity in tumor cells, those studies were
performed using serum starved cells (97-98).
The effects of the mTOR inhibitors on tumor cell radiosensitivity as measured by
clonogenic survival analysis are shown in Figure 12A and B. For this study, cells were
plated at clonogenic density, allowed to attach (5-6 h); the indicated concentration of
inhibitor was added 1h before irradiation. Twenty-four hours after irradiation media was
removed, fresh drug-free media was added and colonies determined 10-14 days later.
Based on the data shown in Figure 10, a concentration of 10 nmol/L rapamycin was used,
which induces the maximum achievable level of mTORC1 inhibition. Rapamycin (10
nmol/L, 25h) alone did not reduce the surviving fraction of U251 cells. Moreover,
addition of rapamycin 1h before irradiation had no effect on the radiosensitivity of U251
cells (Figure 12A). In U251 cells 1 and 2 µmol/L of PP242 added 1h prior to irradiation
increased radiosensitivity in a dose-dependent manner (Figure 12A), consistent with its
dose-dependent mTOR inhibition (Figure 10A), resulting in dose enhancement factors at
a surviving fraction of 0.1 (DEFs) of 1.27 and 1.52, respectively. PP242 alone at 2
µmol/L slightly reduced the U251 surviving fraction to 0.91 ± 0.04 and had no effect on
survival at 1 µmol/L. To determine whether these effects were unique to U251 cells, a
similar analysis was used for MDA-MB-231cells (Figure 12B). Rapamycin (10 nmol/L,
25h) alone had no effect on the surviving fraction of MDA-MB-231 cells and had no
effect on the radiosensitivity of MDA-MB-231 cells. PP242 (2 µmol/L, 25h) alone
reduced surviving fraction of MDA-MB-231 cells to 0.83 ± 0.06; when PP242 was added
1h prior to irradiation enhanced their radiosensitivity with a DEF of 1.34. These data
suggest that in contrast to the allosteric mTOR inhibitor rapamycin, the ATP-competitive
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Figure 12: Effects of mTOR inhibitors on cellular radiosensitivity. A) U251, B) MDAMB-231, and C) MRC9 cells were plated, allowed to attach for 5-6h, and the indicated
concentration of inhibitor was added 1h before irradiation. Twenty-four hours after
irradiation media was removed and fresh drug-free media was added. Colony-forming
efficiency was determined 10-14 days later and survival curves were generated after
normalizing for cell killing from drug alone. Values shown represent the mean + SEM
for 3 independent experiments.
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Figure 13: Influence of PP242 on radiation-induced γH2AX foci. A) U251 and B)
MDA-MB-231 cells were exposed to the indicated dose of PP242 1h prior to irradiation
(2 Gy). Cells were collected at the specified time; γH2AX foci were counted in at least
50 nuclei per condition. Values shown represent the means + SEM for 3 independent
experiments, *p < 0.05 according to Student’s t test (PP242 compared to control).
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inhibitor PP242, which more completely inhibits mTORC1 and inhibits mTORC2,
enhances radiation-induced cell killing.

The same experiment using PP242 was

performed using the normal lung fibroblast line, MRC9 (Figure 12C). PP242 alone had
no effect on MRC9 survival and, in contrast to the tumor cell lines, had no effect on the
radiosensitivity of MRC9 cells.

These results suggest that PP242 induces a tumor

selective increase in radiosensitivity.
The critical lesion responsible for radiation-induced cell death is the DNA double
strand break (DSB). Because γH2AX foci correspond to radiation-induced DSBs and
their dispersal correlates with DSB repair (47-48), the effects of PP242 on radiationinduced γH2AX were evaluated in U251 and MDA-MB-231 cells (Figure 13 A and B).
In this study PP242 was added 1h before irradiation (2 Gy) with γH2AX nuclear foci
determined at times out to 24h. In U251 cells 1 hour after irradiation, no difference in
foci levels was detected between control (vehicle) and PP242 treated cells, suggesting
that mTOR inhibition had no effect on the initial levels of radiation-induced DSBs.
However, at 6 and 24 h after irradiation (2 Gy), the number of γH2AX foci remaining in
the PP242 (1 and 2 µmol/L) treated cells was significantly greater than in control cells.
This effect was PP242 dose-dependent, consistent with the dose-dependent effect on
radiosensitivity in U251 cells.

In MDA-MB-231 cells 1 hour after irradiation, no

difference in foci levels was detected between vehicle treated and PP242 treated cells.
However, at 24h after irradiation, the number of γH2AX foci remaining in the PP242 (2
µmol/L) treated cells was significantly greater than in vehicle treated cells. These data
suggest that PP242 induces radiosensitization via an inhibition of the repair of radiationinduced DNA DSBs.
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Figure 14: The effects of the timing of PP242 treatment on cellular radiosensitivity. AB) U251 and C) MDA-MB-231 cells were plated and allowed to attach. Cells were then
exposed to PP242 (2 µmol/L) either 24h before irradiation (24h Pre-IR), immediately
after (Immediately Post-IR), 1h after (1h Post-IR), or 6h after (6h Post-IR) irradiation.
Media was removed and fresh drug-free media was added 24h after irradiation. Colonyforming efficiency was determined 10-14 days later and survival curves were generated
after normalizing for cell killing from drug alone. Values shown represent the mean +
SEM for 3 independent experiments.
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In the initial treatment protocol evaluating the effects of PP242 on radiosensitivity
(Figure 12) the mTOR inhibitor was added to the culture media 1h before irradiation. To
determine whether this was the optimal exposure protocol for radiosensitization as well
as to generate insight into the mechanisms involved, PP242 (2 µmol/L) was added to
culture media at various times before or after irradiation followed by clonogenic survival
analysis. In each experiment PP242 was removed 24h after exposure to radiation and all
survival curves were generated after normalizing for cell killing caused by PP242
treatment alone.

Addition of PP242 immediately after irradiation enhanced the

radiosensitivity of U251 cells (Figure 14A) with a DEF of 1.60. Addition of PP242 at 1
and 6h after irradiation also resulted in radiosensitization (DEFs of 1.50 and 1.26,
respectively), although the enhancement was substantially less for the 6h time point
(Figure 14B). Treatment of U251 cells with PP242 24h prior to irradiation did not
enhance their radiosensitivity (Figure 14B).

These treatment protocols were also

evaluated using MDA-MB-231 cells (Figure 14C). PP242 exposure for 24h before
irradiation had no effect on the radiosensitivity of MDA-MB-231 cells, whereas drug
addition immediately or 1h after irradiation enhanced radiosensitivity (DEFs of 1.88 and
1.71, respectively) with the sensitization also present, albeit diminished, at the 6h time
point (DEF of 1.31). The data presented in Figures 14 indicate that the PP242-induced
radiosensitization also occurs when the drug was added to culture media after irradiation.
To determine whether the enhancement of tumor cell radiosensitivity measured in
vitro extends to an in vivo tumor model, U251 cells were grown as xenografts in nude
mice. Initially, the ability of PP242 to inhibit mTOR activity in U251 xenografts was
defined. PP242 (100 or 200 mg/kg) was delivered by oral gavage to mice bearing U251
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leg tumors; 6h later tumors were collected and subjected to immunoblot analysis. As
shown in Figure 15A, a consistent reduction of p-AKT and p-4EBP1 levels, indicative of
mTORC2 and mTORC1 inhibition, respectively, was detected in tumors isolated from
mice that received the PP242 at 200 mg/kg. Based on these results, a combination
protocol was designed using 200 mg/kg PP242 and 2 Gy and the consequences on U251
tumor growth rate determined. Specifically, mice bearing U251 leg tumors (~210 mm3)
were randomized into four groups: vehicle, PP242, radiation, and PP242 plus radiation.
PP242 was delivered once a day (200 mg/kg, oral gavage) for four days with the tumor
locally irradiated (2 Gy) 2h after each of the four drug treatments. The growth rates of
U251 tumors exposed to each treatment are shown in Figure 15B. For each group, the
time to grow from 210 mm3 (volume at time of treatment initiation) to 1,000 mm3 was
calculated using the tumor volumes from the individual mice in each group (mean ±
SEM). These data were then used to determine the absolute growth delays (the time in
days for tumors in treated mice to grow from 210 to 1000 mm3 minus the time in days for
tumors to reach the same size in vehicle treated mice).
For U251 tumors (Figure 15B) the absolute growth delays for the PP242 alone
and radiation alone groups were 1.0 ± 0.4 and 12.9 ± 2.1 days, respectively. The growth
delay in mice treated with the combination of PP242 and radiation was 20.0 ± 1.3 days,
which is greater than the sum of the growth delays caused by PP242 alone and radiation
alone. To obtain a dose enhancement factor (DEF) comparing the tumor radioresponse in
mice with and without PP242 treatment, the normalized tumor growth delays were
determined, which accounts for the contribution of PP242 to tumor growth delay induced
by the combination treatment. Normalized tumor growth delay was defined as the time
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Figure 15: The effects of PP242 on radiation-induced tumor growth delay. A) Mice
bearing U251 glioma xenografts were exposed to vehicle or PP242 (oral gavage) at the
indicated dose. Six hours later tumors were collected and subjected to immunoblot
analysis using actin as a loading control. Each lane represents the tumor from an
individual mouse. B) When U251 tumors reached approximately 210 mm3 in size, mice
were randomized into four groups: vehicle, PP242 (200 mg/kg administered once daily
by oral gavage), radiation (2 Gy once daily), and PP242 plus radiation. PP242 was
delivered once a day (200 mg/kg by oral gavage) for four days with the tumor locally
irradiated (2 Gy) 2h after each of the four drug treatments. Each group contained five
mice. Values represent the mean tumor volumes + SEM.

53

in days for tumors to grow from 210 to 1000 mm3 in mice exposed to the
combined modality minus the time in days for tumors to grow from 210 to 1000 mm3 in
mice treated with PP242 only. The DEF, obtained by dividing the normalized tumor
growth delay in mice treated with the radiation/PP242 combination (19.0) by the absolute
growth delay in mice treated with radiation only (12.9), was 1.5. Thus, whereas PP242
delivered alone had no significant effect U251 tumor growth, the ATP-competitive
mTOR inhibitor enhanced the radiation-induced tumor growth delay.
Discussion
Previous investigations into mTOR as a potential target for tumor cell
radiosensitization have focused on rapamycin and various rapalogs. The conclusions of
such studies have been somewhat inconsistent with radiosensitization detected for some
tumor cell lines (97-99) but not others (100-102). Clearly, such inconsistencies may be
attributed to cell type specificity and/or differences in treatment protocols. However, an
additional complicating factor is that rapamycin is an incomplete inhibitor of mTOR
kinase. That is, although rapamycin inhibits the S6 kinase phosphorylation mediated by
mTORC1, it only partially inhibits mTORC1 dependent 4E-BP1 phosphorylation and
does not inhibit mTORC2 activity (90).

Consequently, attempts to correlate

radiosensitization with targeting of mTOR have been limited to the evaluation of S6K
phosphorylation (97-101).

Along these lines, in a study that evaluated multiple

rapamycin concentrations, Murphy et al. showed that exposure of sarcoma cell lines to
300 nmol/L rapamycin resulted in radiosensitization, yet 3 nmol/L was sufficient to
eliminate detectable levels of p-S6K, a concentration that had no effect on
radiosensitivity (98).

Thus, as illustrated by this study, the relationship between
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rapamycin, mTOR activity and radiosensitization is unclear. To better understand the
potential for mTOR to serve as a target for radiosensitization, we defined the
radiosensitivity of tumor cells treated with the ATP-competitive mTOR inhibitor PP242,
which in addition to inhibiting S6 kinase activation, inhibits 4E-BP phosphorylation as
well as the mTORC2 activity (92-93). The data presented here show that for the two
human tumor cell lines evaluated PP242 exposure, in contrast to rapamycin, enhanced
radiation-induced cell killing.
Given the number of mTORC1 and mTORC2 substrates, whether PP242-induced
radiosensitization is initiated via a single downstream event or whether multiple mTOR
substrates are involved remains to be determined. However, as previously reported (32,
92, 103) and shown here, although rapamycin and PP242 inhibit S6 kinase
phosphorylation to approximately the same degree, PP242 exposure results in a
considerably more effective inhibition of 4E-BP1 phosphorylation. Feldman et al (92)
reported that the PP242-mediated inhibition of 4E-BP1 phosphorylation prevents its
release of eIF4E, thus reducing the level of eIF4E available for cap-dependent translation.
Such a scenario would be consistent with our recent data showing that reduced eIF4E
levels increase tumor cell radiosensitivity (104) and suggests that inhibiting the mTOR
mediated phosphorylation of 4E-BP1 at least plays a role in PP242-induced
radiosensitization.
Based on analysis of γH2AX foci induction and dispersion, it appears that PP242mediated radiosensitization is the result of an inhibition of DNA double strand break
repair. Furthermore, the radiosensitization obtained when PP242 was added at times out
to 6h after irradiation suggests that mTOR inhibition affects a later stage in the DNA
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repair process. Although the direct interaction of mTOR or one of its substrates with a
component of the DNA repair machinery cannot be eliminated, the role of mTOR as a
critical regulator of gene translation in response to a variety of stress and environmental
signals may also provide a mechanistic basis for the inhibition of DSB repair in PP242
treated cells. A recent study using microarray analysis of polysome-bound RNA showed
that after PP242 exposure, among the genes whose translation was significantly
suppressed included a number corresponding to DNA repair proteins (103). Ribosome
profiling also indicated that among the genes whose translation was reduced after PP242
exposure were a number involved in DNA repair (105). With respect to the effects
PP242 on radiosensitivity, microarray analysis of polysome-bound RNA has shown that
radiation-induced changes in gene expression can be primarily attributed to translational
control processes (21-22). Moreover, in our recent study using RIP-Chip analysis (104),
irradiation of MDA-MB-231 cells was found to increase eIF4E binding to over 1000
unique transcripts, a significant number of which were associated with the functional
category of DNA Replication, Recombination and Repair. Thus, the PP242-mediated
inhibition of gene translation may also play a role in its radiosensitizing actions, which
will be the subject of future studies.
It has previously been reported that mTOR activity is increased at 15 minutes
after irradiation with a return to control levels by 1h (106). Whereas we did not evaluate
mTOR activity at times less than 1h after irradiation, addition of PP242 at times up to 6h
after irradiation was shown to result in radiosensitization. This would suggest that if
there was a transient increase in mTOR activity after irradiation returning to control
levels by 1h, it was not critical to the mechanism of PP242-induced radiosensitization.
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Furthermore, the study by Contessa et al. used serum-starved cells, which results in a
reduction in basal mTOR activity as compared to standard growth conditions (106). In
contrast, we determined the effects of radiation on mTOR activity using the same
conditions of clonogenic survival analysis (media supplemented with 10% serum).
Whereas PP242 exposure enhanced the radiosensitivity of human tumor cell lines,
the same procedure had no effect on the radiosensitivity of the normal fibroblast line
MRC9. Because mTOR activity in MRC9 cells was reduced by PP242 treatment to the
same extent as in the tumor cells (data not shown), the lack of radiosensitization may
reflect the previously established fundamental differences in mTOR activity and/or
function in tumor versus normal cells (88). To further evaluate the clinical potential of
PP242 delivered in combination with radiotherapy, its effects on mTOR activity and
radiation-induced tumor growth delay were defined in a preclinical model system.
Although PP242 inhibited mTOR activity in U251 xenografts, drug delivery for 4 days
had no significant effect on tumor growth rate, which is in contrast to previous studies
showing substantial tumor growth inhibition with prolonged daily PP242 treatment (93,
107).

However, this drug treatment protocol did result in a significant increase in

radiation-induced tumor growth delay. A number of ATP-competitive mTOR inhibitors
are being evaluated in clinical trials (64). The data presented here showing that PP242
enhances tumor cell radiosensitivity both in vitro and in vivo suggests that these
inhibitors delivered in combination with radiotherapy may be of value as a cancer
treatment strategy.
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CHAPTER 6:
ATP-Competitive mTOR Inhibition by the Clinically Available mTOR Inhibitor
INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic
Adenocarcinoma
Abstract
As shown in Chapter 5, ATP-competitive inhibition of mTOR is required for
tumor radiosensitization. Radiotherapy is a primary treatment modality for the treatment
of locally advanced pancreatic ductal adenocarcinoma, where its use improves local
control and survival. Additionally, constitutive mTOR activation has been shown in
pancreatic adenocarcinoma. The purpose of this study was to define the effects of the
clinically available ATP-competitive mTOR inhibitor, INK128, on pancreatic cancer
radiosensitivity.

Clonogenic survival was used to define the effects of INK128 on

cellular radiosensitivity. In 3 pancreatic cancer cell lines addition of INK128 immediately
after radiation resulted in radiosensitization. Removal of drug from culture media either
12 or 24 but not 6h resulted in radiosensitization. To investigate the mechanism of
radiosensitization, the induction and repair of DNA double strand breaks were evaluated
according to γH2AX foci. INK128 exposure did not influence the initial level of γH2AX
foci after irradiation, but did significantly delay the dispersal of radiation-induced
γH2AX foci. INK128 inhibits mTOR activity in vivo in a time and dose-dependent
manner. Inhibition of mTOR by INK128 inhibits cap-complex formation in PSN1 tumor
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xenografts. Finally, the effects of INK128 on in vivo tumor radiosensitivity were defined
and optimized using both in vitro and in vivo pharmacodynamic data.
Introduction
As described in Chapter 5 our laboratory recently compared the effects of the two
classes of mTOR inhibitors on tumor cell radiosensitivity. ATP-competitive mTOR
inhibition by PP242 enhanced tumor cell radiosensitivity both in vitro and in vivo (108).
However, PP242 has been shown to have poor pharmacokinetic and pharmacodynamics
properties in vivo (105). This led to the development of an analogue of PP242, INK128
(105), which possesses much-improved in vivo pharmacodynamics and pharmacokinetic
properties. INK128 is currently undergoing analysis in the clinical trial setting now (64).
The overall survival rate for patients with pancreatic ductal adenocarcinoma
(PDAC) remains dismal with an overall survival rate of approximately 5% despite
advances in systemic therapy (109-110). Gemcitabine is the standard systemic therapy
(111), however local control is an important component of therapy as it has been reported
that approximately one-third of pancreatic cancer mortality is due to local disease (112).
The importance of local control is highlighted by clinical data showing the combination
of radiation with gemcitabine significantly prolongs survival when compared to
gemcitabine alone (113). However, whereas there have been improvements in therapy,
the prognosis for patients with pancreatic adenocarcinoma still remains poor.

This

emphasizes the need for the development of agents aimed at improving the efficacy of
radiotherapy. High incidences of activating mutations in K-RAS have been reported in
PDAC (114).

These activating mutations in K-RAS increase MAPK as well as

PI3K/AKT/mTOR signaling (114). Consistent with the role of activating mutations in K-
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RAS it has been reported that approximately 70% of PDAC have constitutive mTOR
activation (115). Given the proposed role of eIF4E and mTOR as determinants of tumor
radiosensitivity, as well as the reported activation of mTOR in PDAC, the effects of the
clinically available mTOR ATP-competitive inhibitor INK128 on pancreatic cancer cell
radiosensitivity were defined.

The data presented here indicate that mTORC1/2

inhibition by INK128 enhances PDAC radiosensitivity in vitro and in vivo and that this
effect involves inhibition of DNA double strand break repair. Furthermore, these data
provide preclinical insight into the design of protocols combining radiation and mTOR
ATP-competitive inhibitors.
Results
To investigate the effects of mTOR inhibition by the mTOR ATP-competitive
inhibitor INK128 on pancreatic cancer cell radiosensitivity, 3 human pancreatic cancer
cell lines were used: Miapaca-2, Panc1, and PSN1. Initially mTORC1 and mTORC2
activity was determined in each cell line after various length of exposure to INK128
(Figure 16). Towards this end, the levels p-4E-BP1 (t37/46) were used as readouts for
mTORC1 activity; p-AKT (s473) was used as a marker for mTORC2 activity. INK128
exposure in all three cell lines reduced activity of mTORC1 and mTORC2 in a timedependent manner, consistent with reports in the literature (105).
The effects of INK128 on pancreatic cancer cell radiosensitivity as measured by
clonogenic survival analysis are shown in Figure 17A-C. For this study cells were plated
at clonogenic density, allowed to attach overnight, irradiated, followed immediately by
adding the specified concentration of INK128. This protocol was chosen based upon our
recently published work showing maximal radiosensitization by the ATP-competitive
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Figure 16: Effects of INK128 on mTORC1/2 activity. A) The indicated cells were
treated with the specified dose of inhibitor. Cells were collected at the specified time
points and subjected to immunoblot analysis. Actin was used as a loading control.
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Figure 17: Effects of INK128 on cellular radiosensitivity. A) Miapaca-2, B) Panc1, C)
PSN1, and D) MRC9 cells were plated, allowed to attach overnight, irradiated and the
indicated concentration of inhibitor was added immediately after radiation. Twenty-four
hours after irradiation media was removed and fresh drug-free media was added.
Colony-forming efficiency was determined 10-14 days later and survival curves were
generated after normalizing for cell killing from drug alone. Values shown represent the
mean + SEM for 3 independent experiments.
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mTOR inhibitor PP242 when added immediately after radiation (108). Twenty-four
hours after irradiation media was removed, fresh drug-free media was added and colonies
determined 10-14 days later. INK128 treatment alone reduced the surviving fraction to
0.85 ± 0.02 in Miapaca-2 cells. In contrast, INK128 treatment had no effect on the
surviving fraction of Panc1 or PSN1 cells. In all 3 pancreatic cancer cell lines treatment
with INK128 immediately after irradiation resulted in an increase in cellular
radiosensitivity. The dose-enhancement factors at a surviving fraction of 0.1 (DEF) were
1.33, 1.45, and 1.37 for Miapaca-2, Panc1, and PSN1 cells respectively. The same
experiment using INK128 was performed using the normal lung fibroblast line, MRC9
(Figure 17D). INK128 treatment alone reduced the MRC9 surviving fraction to 0.73 ±
0.05, and in contrast to the 3 pancreatic cancer cell lines had no significant effect on the
radiosensitivity of MRC9 cells. These results are consistent with our previous results
where PP242 enhanced tumor but not normal cell radiosensitivity (108). These results
suggest that INK128 treatment causes an increase in the radiosensitivity of pancreatic
cancer cells.
The critical lesion responsible for radiation-induced cell death is the DNA double
strand break (DSB). Because γH2AX foci correspond to radiation-induced DSBs and
their dispersal correlates with DSB repair (47-48), the effects of INK128 on radiationinduced γH2AX were evaluated in PSN1 cells (Figure 18). In this study the same
treatment protocol used for the clonogenic survival assays above was used, which
consisted of adding INK128 immediately after irradiation (2 Gy) with γH2AX nuclear
foci determined at times out to 24h. No difference in foci levels was detected between
control (vehicle) and INK128 treated cells 1 hour after irradiation, suggesting that mTOR
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Figure 18: Influence of INK128 on radiation-induced γH2AX foci. A) PSN1 cells were
exposed to the indicated dose of INK128 immediately after irradiation (2 Gy). Cells
were collected at the specified time; γH2AX foci were counted in at least 50 nuclei per
condition. Values shown represent the means + SEM for 3 independent experiments, *p
< 0.05 according to Student’s t test (INK128 compared to control).
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inhibition has no effect on the initial levels of radiation-induced DSBs. However at 6 and
24h after irradiation, the number of γH2AX foci reaming was significantly greater in the
inhibition has no effect on the initial levels of radiation-induced DSBs. However at 6 and
24h after irradiation, the number of γH2AX foci reaming was significantly greater in the
INK128 treated cells relative to control cells. These data are consistent with our recently
published data showing eIF4E knockdown and pharmacologic inhibition of eIF4E by the
mTOR ATP-competitive inhibitor PP242 delay the dispersal of radiation-induced γH2AX
foci. These results suggest that INK128-mediated radiosensitization is caused by an
inhibition of radiation-induced DNA DSB repair.
Understanding the pharmacodynamic and pharmacokinetic properties of a drug is
critical for the rational design of protocols combining radiation and chemotherapies. To
begin to evaluate these effects in a preclinical setting Miapaca-2 and PSN1 cells were
grown as xenografts in nude mice. The ability of INK128 to inhibit mTOR activity in
both Miapaca-2 and PSN1 xenografts (Figure 19 A and B respectively) was determined
via immunohistochemical analysis of p-4E-BP1 (t37/46) an established marker for
mTOR activity. INK128 (1 or 3 mg/kg) was delivered by oral gavage to mice bearing
Miapaca-2 or PSN1 tumor xenografts; tumors were collected either 2 or 6h after
drugging, and processed for immunohistochemical analysis.

In Miapaca-2 tumor

xenografts treatment with INK128 (both 1 and 3 mg/kg) inhibited mTOR activity 2 hours
after the initial dose as judged by a decrease in p-4E-BP1 staining, with a more
pronounced inhibition with the 3 mg/kg dose. 6 hours after INK128 treatment mTOR
activity is beginning to increase, albeit not to control levels, with a greater return to
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A. Miapaca-2

B. PSN1

Figure 19: The effects of INK128 treatment on mTOR activity in pancreatic tumor
xenografts. Mice bearing Miapaca-2 (A) or PSN1 (B) xenografts were exposed to
vehicle or the indicated dose of INK128 (oral gavage). Tumors were collected 2 or 6
hours later and prepared for immunohistochemical staining. Sections were probed with an
antibody specific to p-4E-BP1 T37/46 followed by staining with a FITC coupled
secondary antibody (green). Nuceli were visualized with DAPI (blue). Each image is of
representative of at least two mice per treatment group.
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baseline in the 1 mg/kg treated tumors. In PSN1 tumor xenografts treatment with both 1
and 3 mg/kg inhibited mTOR activity to a similar degree 2 hours after the initial drug
dose. Consistent with the results obtained for Miapaca-2 tumor xenografts, 6 hours after
drug dosing mTOR activity is beginning to return. These results suggest that INK128
inhibits mTOR activity in a dose and time-dependent manner in pancreatic tumor
xenografts.
As described in the Introduction, mTOR controls eIF4F cap-complex formation
primarily by phosphorylation of the translation inhibitor 4E-BP1. Upon phosphorylation,
4E-BP1 is released from the 5’ mRNA cap followed by binding of eIF4G and
subsequently the initiation of translation (32).

To extend the immunohistochemical

analysis of INK128-mediated mTOR inhibition to its effects on in vivo cap-complex
formation, m7-GTP batch chromatography was employed on tumor PSN1 tumor
xenografts treated with INK128 (3 mg/kg) and collected 2 or 6 hours later (Figure 20).
m7-GTP batch chromatography is a standard approach for assessing eIF4F cap-complex
formation (25, 30). Consistent with the constitutive phosphorylation of 4E-BP1 seen by
immunohistochemical staining (Figure 19) vehicle treated mice have substantial eIF4F
cap-complex formation as judged by bound eIF4G. Treatment with INK128 decreased
eIF4F cap-complex as evidenced by an increase in bound 4E-BP1 and decrease in bound
eIF4G. Furthermore, consistent with the time-dependent effect on mTOR activity seen
by immunohistochemical staining, the effects of INK128 treatment on eIF4F capcomplex formation were time dependent with bound eIF4G beginning to increase 6 hours
after drugging. These results suggest that in vivo mTOR inhibition by the mTOR ATPcompetitive inhibitor, INK128, results in a decrease in eIF4F cap-complex formation.
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Figure 20: The effects of INK128 on PSN1 tumor xenograft eIF4F complex formation.
A) m7-GTP affinity chromatography was performed on PSN1 tumor xenografts that were
exposed to 3 mg/kg INK128 (oral gavge) or vehicle and collected at the specified
timepoints. m7-GTP bound proteins were resolved via SDS-PAGE followed by
immunoblot analysis. eIF4E was used as a loading control. Each lane represents the
tumor from an individual mouse.
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To determine whether the observed radiosensitization in vitro could be translated to an in
vivo setting a tumor regrowth delay experiment was performed using PSN1 tumor
xenografts in nude mice. Based upon the immunohistochemical analysis of INK128
treatment in PSN1 xenografts, a combination protocol was designed using INK128 and a
single fraction of 6 Gy. Specifically, mice bearing PSN1 leg tumors (~180mm3) were
randomized into four groups: vehicle, INK128 (3 mg/kg, delivered by oral gavage),
radiation (6 Gy), and the combination of INK128 and radiation. INK128 was delivered
once immediately after the locally delivered radiation dose. The growth rates of PSN1
tumors exposed to each treatment are shown in Figure 21A. As shown there was no
difference in the growth rates of mice receiving radiation or mice that received the
combination of radiation and a single dose of INK128. As such, this treatment protocol
did not result in an enhancement of in vivo tumor radiosensitivity. The initial treatment
protocol evaluating the effects of INK128 on pancreatic cancer cell radiosensitivity in
vitro consisted of adding INK128 to culture media and removing drug 24h after radiation.
In light of the lack of sensitization seen in the single dose in vivo tumor growth delay
experiments as well as the immunohistochemical analysis showing mTOR activity
beginning to return as early as 6h post a single drug dose we postulated that duration of
mTOR inhibition post-radiation could be an important factor in the determining the
radiosensitization seen with INK128 treatment. To begin to address this question in vitro
we performed clonogenic survival analysis with PSN1 cells using a modified treatment
protocol. This protocol consisted of addition of INK128 to culture media immediately
after radiation and removing the drug 6, 12, or 24h post-radiation. The results of this
analysis are shown in Figure 21B. In all 3 treatment protocols INK128 alone had no
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Figure 21: The effects of duration of mTOR inhibition on in vitro and in vivo radiosensitivity. . When
PSN1 tumor xenografts reached approximately 180 mm3 in size, mice were randomized into four groups:
vehicle, INK128 (oral gavage), radiation, and INK128 plus radiation. A) The tumors were locally
irradiated (6 Gy) followed by a single dose of INK128 (3 mg/kg.) Each group contained six mice. Values
represent the mean tumor volumes + SEM. B.) PSN1 cells were plated at clonal density and allowed to
attach overnight irradiated and INK128 (4µM) was added immediately after irradiation. At the specified
times after irradiation media was removed and fresh drug-free media was added. Colony-forming
efficiency was determined 10-14 days later and survival curves were generated after normalizing for cell
killing from drug alone. DEFs were calculated at a surviving fraction of 0.1. Values shown represent the
mean + SEM for 3 independent experiments. C) INK128 was delivered twice daily (1.5 mg/kg) for two
days with the tumor locally irradiated (6Gy) 1h after the first drugging followed by a second drug dose
delivered 6h later. INK128 alone contained 5 mice and all other group contained 6 mice. Values represent
the mean tumor volumes + SEM. D) INK128 was delivered twice daily (1.5 mg/kg) for 4 days with the
tumor locally irradiated (2 Gy) 1h after the first drugging followed by a second drug dose delivered 6h
later. On the fifth day INK128 was delivered twice with each dose separated by 7h. The INK128/radiation
combination group contained 6 mice and all other group contained 7 mice. Values represent the mean
tumor volumes + SEM.
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effect on the surviving fraction. The treatment protocol where INK128 was removed 6h
post-irradiation had no significant effect on the radiosensitivty of PSN1 cells, whereas
removing INK128 12 or 24h after irradiation enhanced PSN1 tumor cell radiosensitivity
with DEFs of 1.23 and 1.33 respectively. These data suggest that duration of mTOR
inhibition after radiation is an important determinant of the radiosensitizing effects seen
with INK128 treatment.
In light of the in vitro data suggesting that sustained mTOR inhibition beyond 6h
is critical for radiosensitization with INK128 as well as immunohistochemical analysis
and eIF4F cap-complex formation data in PSN1 tumors suggesting mTOR activity begins
to return as early as 6h after a single drug exposure, a modified tumor growth delay
experiment combining radiation and INK128 was designed. Specifically, mice bearing
PSN1 tumor xenografts were randomized into four treatment groups: vehicle, INK128
(1.5 mg/kg), radiation, or combination treatment. This experiment was performed with a
single dose of locally delivered radiation (6 Gy) given 1h after INK128 treatment.
INK128 was given again 6h after irradiation, followed the next day by two additional
INK128 doses separated by 7h. The effects of the different treatment protocols on tumor
growth are shown in Figure 21C. For each group the time to grow from 180mm3
(volume of tumors at initiation of treatment) to 1000mm3 was calculated using the tumor
volumes from the individual mice in each group (mean ± SEM). These data were then
used to determine the absolute growth delays. For PSN1 tumors the absolute growth
delay for radiation alone was 6.3± 0.7 days. INK128 treatment alone had no significant
effect on tumor growth delay. For tumors treated with the combination of INK128 and
radiation the absolute growth delay was 12.3 ± 0.4 days. Importantly, this growth delay

71

is greater than the sum of the growth delays from the individual treatments indicative of
an enhancement of tumor radiosensitivity. To obtain a dose enhancement factor (DEF)
comparing the tumor radioresponse in mice with and without INK128 treatment, the
normalized tumor growth delays were determined, which accounts for the contribution of
INK128 to tumor growth delay induced by the combination treatment. Normalized tumor
growth delay was defined as the time in days for tumors to grow from 180 to 1000 mm3
in mice exposed to the combined modality minus the time in days for tumors to grow
from 180 to 1000 mm3 in mice treated with INK128 only. The DEF, obtained by
dividing the normalized tumor growth delay in mice treated with the radiation/INK128
combination (12.3) by the absolute growth delay in mice treated with radiation only (6.3),
was 2.0.

Consistent with in vitro data, these in vivo data suggest extended mTOR

inhibition for periods longer than 6h are required for INK128-induced radiosensitization.
To extend the single dose in vivo tumor growth delay study to a clinically relevant
radiation protocol, a tumor growth delay experiment was performed with fractionated
radiation. Specifically, mice bearing PSN1 tumor xenografts were randomized into four
treatment groups: vehicle, INK128 (1.5 mg/kg), radiation (2Gy x 4), or combination
treatment. This experiment was performed with locally delivered radiation (2 Gy) given
1h after INK128 treatment. INK128 was given again 6h after irradiation. This was
performed for four consecutive days. On the fifth day two additional INK128 doses
separated by 7h were given. The effects of the different treatment protocols on tumor
growth are shown in Figure 21D. For each group the time to grow from 180mm3
(volume of tumors at initiation of treatment) to 1000mm3 was calculated using the tumor
volumes from the individual mice in each group (mean ± SEM). These data were then
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used to determine the absolute growth delays (the time in days for tumors in treated mice
to grow from 180mm3 to 1000 mm3 minus the time in days for tumors to reach the same
size in vehicle treated mice). For PSN1 tumors the absolute growth delays for INK128
alone and radiation alone were 1.0 ± 0.6 and 3.7 ± 0.6 days respectively. For tumors
treated with the combination of INK128 and radiation the absolute growth delay was 10.1
± 1.8 days. Importantly, this growth delay is greater than the sum of the growth delays
from the individual treatments, indicative of an enhancement of tumor radiosensitivity.
Normalized tumor growth delay was defined as the time in days for tumors to grow from
180 to 1000 mm3 in mice exposed to the combined modality minus the time in days for
tumors to grow from 180 to 1000 mm3 in mice treated with INK128 only. The DEF,
obtained by dividing the normalized tumor growth delay in mice treated with the
radiation/INK128 combination (9.1) by the absolute growth delay in mice treated with
radiation only (3.7), was 2.5. Consistent with the single radiation dose experiment the
combination of INK128 with a clinically relevant fractionated radiation protocol
enhanced in vivo tumor radiosensitivity.
Discussion
Based upon the analysis of radiation-induced γH2AX foci after radiation in PSN1
cells treated with INK128 it appears that the mechanism of radiosensitization involves an
inhibition of DNA DSB repair. These results are consistent with our recently published
results showing mTOR ATP-competitive inhibition of tumor cell lines resulted in an
inhibition of DNA DSB repair.

Furthermore in vitro clonogenic survival analysis

showing maintenance of mTOR inhibition for greater than 6h was required for effective
radiosensitization, suggests that INK128 inhibits a later stage of DNA DSB repair.
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Although the direct interaction of mTOR or one of its substrates with a component of the
DNA repair machinery cannot be eliminated, the role of mTOR as a critical regulator of
gene translation in response to a variety of environmental and stress signals may provide
a mechanistic basis for the inhibition of DSB repair in INK128 treated cells. A recent
study using microarray analysis of polysome-bound RNA showed that after PP242
exposure, the translation of genes suppressed included many corresponding to DNA
repair proteins (103). Furthermore, another recent report using ribosome profiling to
identify actively translated mRNAs showed INK128 treatment inhibited the translation of
many mRNAs encoding proteins related to DNA DSB repair (105). As microarray
analysis of polysome-bound RNA has shown that radiation-induced changes in gene
expression can be primarily attributed to translational control processes (21-22) it is
possible to conclude that INK128’s effects on radiosensitivity are due in part to inhibition
of cap-dependent translation. Moreover, in our recent study using RIP-Chip analysis
(104), irradiation of MDA-MB-231 cells was found to increase eIF4E binding to over
1000 unique transcripts, a significant number of which were associated with the
functional category of DNA Replication, Recombination and Repair. Thus, the INK128mediated inhibition of gene translation may also play a role in its radiosensitizing actions,
which will be the subject of future studies.
mTOR is the primary kinase involved in the regulation of cap-dependent
translation initiation due in part to it control of 4E-BP1 phosphoryaltion (49). Using
immunohistochemical staining we showed a time and dose-dependent inhibition of
mTOR activity in both Miapaca-2 and PSN1 tumor xenografts. It has been shown that
inhibition of mTOR by an ATP-competitive inhibitor results in the decrease of 4E-BP1
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phosphorylation (92, 103). This effect has been translated to an increase in binding of
4E-BP1 and a concomitant decrease in the amount of eIF4G binding to the 5’ mRNA cap
in vitro (93). However, to the best of our knowledge, the effects of mTOR ATPcompetitive inhibition on eIF4F cap-complex formation have not been evaluated in vivo.
Using m7-GTP batch chromatography in PSN1 tumor xenografts we showed inhibition of
mTOR activity by INK128 does indeed translate to an inhibition of cap-complex
formation in human tumor xenografts. This inhibition of cap-dependent translation in
vivo is consistent with the hypothesis that an inhibition of radiation-induced translation is
involved in the mechanism of radiosensitization by the mTOR ATP-competitive inhibitor
INK128.
The study of in vivo pharmacodynamics and pharmacokinetic properties of a drug
is important for the potential clinical translation of a drug, particularly when designing
protocols combining multiple treatment modalities. These effects are evidenced by our in
vivo tumor growth delay experiments as well as in vitro clonogenic survival data. The
initial in vivo tumor growth delay experiment showing a lack of radiosensitization with a
single dose of INK128 given immediately after radiation, emphasize the understanding of
target engagement in vivo. Both immunohistochemical analysis as well as analysis of
cap-complex formation in vivo suggest mTOR activity in PSN1 tumor xenografts is
beginning to return to baseline as early as 6h after the initial drug treatment. When
combined with the in vitro clonogenic survival data suggesting that mTOR inhibition for
greater than 6h is required for effective radiosensitization, a redesign of the protocol to
include additional drug dosing was performed. In this protocol, INK128, when given
twice daily with radiation, significantly enhanced radiation-induced tumor growth delay,
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once again emphasizing the need for a thorough understanding of the pharmacodynamics
and pharmacokinetics of drugs both in vitro and in vivo.

There are several ATP-

competitive inhibitors currently in clinical trials (including INK128) (64). The data
presented here showing that INK128 enhances pancreatic cancer radiosensitivity both in
vitro and in vivo suggests that these inhibitors delivered in combination with radiotherapy
may be of value as a treatment strategy for pancreatic cancer.
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CHAPTER 7
Overall Conclusions
As described in the Chapter 1, radiation-induced control of gene expression
appears to be controlled primarily at the level of mRNA translation (21-22). The data
presented in this thesis begin to elucidate the specific role of critical components of the
translational machinery in determining the cellular response to ionizing radiation. While
there are numerous regulatory proteins in involved in translational control, eIF4E, S6K,
and the mTOR kinase, which regulates both eIF4E and S6K, affect the rate-limiting step
of mRNA translation; translation initiation (82). As such the work presented in this
thesis focused on determining the role of each protein in the radiation response. In the
case of both eIF4E and S6K, the initial studies aimed at determining the role of each
protein in controlling cellular radiosensitivity focused on the use of siRNAs targeting
these components. In each case, siRNA specific to eIF4E and S6K enhanced the cellular
radiosensitivity of tumor lines of various histologies.
For a radiosensitizing compound to be clinically useful it must enhance the
response of the tumor to radiation while sparing the normal tissue, as normal tissue
toxicity is the dose-limiting factor in radiotherapy. As described previously, inhibition of
eIF4E, S6K, and mTOR expression or activity enhanced the radiosensitivity of various
tumors, while having no effect on the in vitro radiosensitivity of normal tissues. While
these were studies were performed only in vitro they begin to address whether these
regulatory components of the translational machinery could potentially serve as tumor
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specific targets.

While the exact reason for this tumor specificity remains to be

determined it is possible to speculate that the established differences in translational
regulation between tumor and normal cells may be explanatory. In the context of cellular
signaling, tumors have been shown to have aberrant activation of numerous signaling
pathways that transduce their signals through mTOR/eIF4E/S6K and hence activate
mRNA translation (e.g. RTK, RAS/MAPK, and PI3K) (34, 57-58). In fact 4E-BP1, the
major regulator of eIF4E activity, has been referred to as a funnel factor (56), in so much
as it exists as a downstream effector of many of the aforementioned hyper-activated
oncogenic signaling pathways. Specifically, the translational response to radiation has
been shown to differ greatly in tumor and normal cells (21). Lastly, in the context of
combination therapy with standard DNA damaging chemotherapies and translation
inhibitors, the combination was only synergistic when tumors had deregulated translation
(85). As such it is possible to conclude that the tumor specific radiosensitization seen
with inhibition of these components of the translational machinery may be due to
activation of oncogenic signaling pathways leading to an aberrant translational program.
Future studies comparing the translational response of tumor versus normal cells in the
context of mTOR inhibition may be used to begin to understand the tumor selectivity of
targeting the above-mentioned components of the translational machinery.
mRNA translation and components of the translational machinery have been
implicated in cellular transformation and oncogenesis (28). All three critical components
of the translational machinery studied in this thesis have individually been shown to be
critical for various aspects of cancer initiation and progression (e.g. cell growth, invasion,
and cellular transformation) (34, 39, 66, 88). Overexpression and hyperactivity of both
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eIF4E (41-42) and the mTOR kinase (60) have been shown to impart a poor prognosis on
patients with various tumors . As such, agents aimed at targeting these components have
been developed and are currently available for clinical use (64). Some of the agents such
as the ISIS eIF4E antisense, mTOR ATP-competitive inhibitors (e.g. INK128), and S6K
inhibitors (e.g. LY2584702) have been mentioned previously in this dissertation. The
work presented here begins to highlight the importance of the translational machinery in
determining tumor survival after radiation.

Given the clinical availability of agents

targeting the translational machinery as well as the data presented showing that inhibition
of these components enhances tumor cell radiosensitivity, it is logical to suggest
evaluation of these agents in combination with radiation in the clinical trial setting.
On the basis of analysis γH2AX induction and dispersal, both eIF4E as well as
competitive mTOR inhibition appear to inhibit the repair of radiation-induced DNA
DSBs. Although direct interaction of eIF4E, mTOR, or an mTOR substrate with a
component of the DNA repair machinery cannot be eliminated, the critical role of both
proteins in the translational response to a wide variety of environmental and stress signals
may provide a mechanistic basis for the observed inhibition of DNA DSB repair. Several
studies have shown that inhibition of mTOR activity results in inhibition of translation of
mRNA corresponding to DNA repair genes (103, 105). As detailed in Chapter 2, using
microarray analysis of eIF4E-bound mRNAs, radiation was shown to induce eIF4E
binding to more than 1000 unique transcripts. A significant proportion of these mRNAs
encode proteins related to DNA replication, recombination, and repair. In agreement
with our results a recent study using microarray analysis of polyribosome-bound mRNA
found that radiation-induced translation of mRNAs that were involved in DNA damage
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repair, several of which overlapped with proteins our study showed to be increasingly
bound to eIF4G after irradiation. Importantly, Singh and colleagues (55) have shown that
DNA DSBs are generated not only from the initial radiation exposure, but also from
chemical processing occurring for hours after exposure to radiation. In this situation, a
rapid induction in DNA damage response proteins may contribute to cell survival after
radiation. While our initial studies with eIF4E knockdown were unable to determine
whether the tumor cell radiosensitization was due to an inhibition of radiation-induced
gene expression, or changes in mRNA translation prior to irradiation, subsequent studies,
with post-radiation addition of PP242 and INK128, suggest that the mechanism of
radiosensitization involves an inhibition of a radiation-induced process (e.g. gene
translation). Thus, mTOR inhibition in the context of altering the radiation-induced
translational response is currently the focus of additional studies in our laboratory.
In summary, the data provided in this thesis have begun to characterize the role of
the translational machinery in determining the cellular response to radiation. While there
is work that remains to be completed in understanding the exact mechanisms involved in
the radiosensitization seen by targeting components of the translational machinery, we
believe the work presented in this thesis argue that targeting components of the
translational machinery is a strategy that deserves consideration for evaluation in the
clinical trial setting.
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Table A1: List of 1124 genes increasingly bound to eIF4E after irradiation
Fold
Increas
e
2.2

3.1
1.9

Gene Description

ABCA11

ATP-binding
cassette, subfamily A (ABC1),
member 11
(pseudogene)
abhydrolase
domain containing
4
abhydrolase
domain containing
6
activator of basal
transcription 1
acyl-Coenzyme A
dehydrogenase
family, member 8
acetyl-Coenzyme
A acetyltransferase
1 (acetoacetyl
Coenzyme A
thiolase)
acyl-CoA
thioesterase 7
acyl-CoA
thioesterase 9
ARP5 actin-related
protein 5 homolog
(yeast)
aarF domain
containing kinase 2
ADP-dependent
glucokinase
adenylosuccinate
lyase
1-acylglycerol-3phosphate Oacyltransferase 2
(lysophosphatidic
acid
acyltransferase,
beta)
absent in
melanoma 1-like
aldo-keto reductase
family 1, member
C2 (dihydrodiol
dehydrogenase 2;
bile acid binding
protein; 3-alpha
hydroxysteroid

ABHD4
ABHD6

1.5

ABT1

1.8

ACAD8

1.8

	
  

Gene
Symbol

ACAT1

1.7

ACOT7

1.5

ACOT9

1.6

ACTR5

3

ADCK2

1.8

ADPGK

2.4

ADSL

2.2

AGPAT2

1.5

AIM1L

1.5

AKR1C2

dehydrogenase,
type III)
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1.8

AKR7A2

aldo-keto reductase
family 7, member
A2 (aflatoxin
aldehyde
reductase)
alkB, alkylation
repair homolog (E.
coli)
autocrine motility
factor receptor
anaphase
promoting
complex subunit 5
ankyrin repeat
domain 40
annexin A11

4.1

ALKBH

1.9

AMFR

1.7

ANAPC5

1.8
4.5

ANKRD
40
ANXA11

1.5

AP4M1

1.7

APBB1

2

APLP2

1.5

APOL3

adaptor-related
protein complex 4,
mu 1 subunit
amyloid beta (A4)
precursor proteinbinding, family B,
member 1 (Fe65)
amyloid beta (A4)
precursor-like
protein 2
apolipoprotein L, 3

1.5

APTX

aprataxin

2.9

ARF3

1.5

ARL6IP5

10.8

ARPC2

1.5

ARRB2

ADP-ribosylation
factor 3
ADP-ribosylationlike factor 6
interacting protein
5
actin related
protein 2/3
complex, subunit
2, 34kDa
arrestin, beta 2

1.8

ASB13

11.2

ASCIZ

2.3

ATP1B3

ankyrin repeat and
SOCS boxcontaining 13
ATM/ATRSubstrate Chk2Interacting Zn2+finger protein
ATPase, Na+/K+
transporting, beta 3

polypeptide
1.7

1.6

	
  

ATP5B

ATP5C1

1.5

ATP5L

2

ATP6V0
E

1.6

ATP6V1
D

1.8

ATP8A2

1.8

ATPAF2

2.2

B4GALT
4

8.6

BBP

2.1

BBS4

1.7

BCAT1

2.6

BCL10

4.7

BCL2L1
1

3.5

BIRC5

2.1

BMPR1A

ATP synthase, H+
transporting,
mitochondrial F1
complex, beta
polypeptide
ATP synthase, H+
transporting,
mitochondrial F1
complex, gamma
polypeptide 1
ATP synthase, H+
transporting,
mitochondrial F0
complex, subunit g
ATPase, H+
transporting,
lysosomal 9kDa,
V0 subunit e
ATPase, H+
transporting,
lysosomal 34kDa,
V1 subunit D
ATPase,
aminophospholipid
transporter-like,
Class I, type 8A,
member 2
ATP synthase
mitochondrial F1
complex assembly
factor 2
UDPGal:betaGlcNAc
beta 1,4galactosyltransfera
se, polypeptide 4
Beta-amyloid
binding protein
precursor
Bardet-Biedl
syndrome 4
branched chain
aminotransferase 1,
cytosolic
B-cell
CLL/lymphoma 10
BCL2-like 11
(apoptosis
facilitator)
baculoviral IAP
repeat-containing 5
(survivin)
bone
morphogenetic
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1.7

BNIP2

1.9

BNIP3

1.7

BRE

2.3

BTG1

1.6

C10orf57

2.7

C10orf61

2

C10orf97

1.7

C11orf24

4.8

C12orf41

1.6

C12orf49

1.6

C12orf52

1.7

C14orf13
8

1.5

C14orf17
2

1.5

C16orf45

1.7

C16orf58

1.6

C17orf39

1.8

C19orf2

protein receptor,
type IA
BCL2/adenovirus
E1B 19kDa
interacting protein
2
BCL2/adenovirus
E1B 19kDa
interacting protein
3
brain and
reproductive
organ-expressed
(TNFRSF1A
modulator)
B-cell
translocation gene
1, anti-proliferative
chromosome 10
open reading frame
57
chromosome 10
open reading frame
61
chromosome 10
open reading frame
97
chromosome 11
open reading frame
24
chromosome 12
open reading frame
41
chromosome 12
open reading frame
49
chromosome 12
open reading frame
52
chromosome 14
open reading frame
138
chromosome 14
open reading frame
172
chromosome 16
open reading frame
45
chromosome 16
open reading frame
58
chromosome 17
open reading frame
39
chromosome 19
open reading frame

2
1.5
8.2

C1orf144

7.4

C1orf163

1.7

C1orf174

1.8

C1orf33

4.8

C20orf11
1

1.7

C20orf24

3

C20orf29

5.3

C20orf44

3.8

C20orf45

3

	
  

C19orf50

C21orf91

4.8

C2orf43

1.5

C3orf18

1.7

C3orf37

1.8

C5orf30

3.7

C6orf106

4

C6orf49

1.8

C6orf82

chromosome 19
open reading frame
50
chromosome 1
open reading frame
144
chromosome 1
open reading frame
163
chromosome 1
open reading frame
174
chromosome 1
open reading frame
33
chromosome 20
open reading frame
111
chromosome 20
open reading frame
24
chromosome 20
open reading frame
29
chromosome 20
open reading frame
44
chromosome 20
open reading frame
45
chromosome 21
open reading frame
91
chromosome 2
open reading frame
43
chromosome 3
open reading frame
18
chromosome 3
open reading frame
37
chromosome 5
open reading frame
30
chromosome 6
open reading frame
106
chromosome 6
open reading frame
49
chromosome 6
open reading frame
82

1.6

C7orf26

10

C8orf30
A

3

C9orf78

5.4

C9orf82

4.1

CABIN1

6.1

CALM1

4.3

CAMLG

2.3

CAMTA
2

4.7

CASP3

1.8

CASP9

1.5

CAV2

chromosome 7
open reading frame
26
chromosome 8
open reading frame
30A
chromosome 9
open reading frame
78
chromosome 9
open reading frame
82
calcineurin binding
protein 1
calmodulin 1
(phosphorylase
kinase, delta)
calcium
modulating ligand
calmodulin binding
transcription
activator 2
caspase 3,
apoptosis-related
cysteine peptidase
caspase 9,
apoptosis-related
cysteine peptidase
caveolin 2

2.2

CCDC13
2
CCNA1

coiled-coil domain
containing 132
cyclin A1

1.7

CCNA2

cyclin A2

1.6

CCNB1I
P1

2.5

CCNE2

cyclin B1
interacting protein
1
cyclin E2

1.9

CCS

3

CD164

1.7

CD59

4.3

CD63

1.6

CDC2

3.9
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copper chaperone
for superoxide
dismutase
CD164 antigen,
sialomucin
CD59 antigen p1820 (antigen
identified by
monoclonal
antibodies 16.3A5,
EJ16, EJ30, EL32
and G344)
CD63 antigen
(melanoma 1
antigen)
cell division cycle
2, G1 to S and G2
to M

4.9

CDC25C

2.2

CDC42E
P2

1.6

CDCA4

1.7

CDKL3

1.9

CDKN1
A

1.7

CDKN2C

1.5

CDKN3

2.3

CDYL

2

CENPB

3.2

CENPO

6.1

CEP57

1.5

CEPT1

2.3

7.6

CHEK1

3.1

CHST10

1.8

CIDEC

1.6

CINP

2.2

CIR

3.1

CLIC1

5.5

	
  

CHCHD7

CLIC4

cell division cycle
25C
CDC42 effector
protein (Rho
GTPase binding) 2
cell division cycle
associated 4
cyclin-dependent
kinase-like 3
cyclin-dependent
kinase inhibitor 1A
(p21, Cip1)
cyclin-dependent
kinase inhibitor 2C
(p18, inhibits
CDK4)
cyclin-dependent
kinase inhibitor 3
(CDK2-associated
dual specificity
phosphatase)
chromodomain
protein, Y-like
centromere protein
B, 80kDa
centromere protein
O
centrosomal
protein 57kDa
choline/ethanolami
ne
phosphotransferase
1
coiled-coil-helixcoiled-coil-helix
domain containing
7
CHK1 checkpoint
homolog (S.
pombe)
carbohydrate
sulfotransferase 10
cell death-inducing
DFFA-like effector
c
cyclin-dependent
kinase 2interacting protein
CBF1 interacting
corepressor
chloride
intracellular
channel 1
chloride
intracellular
channel 4
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2

CLINT1

1.5

CLN5

1.7

CLTA

7.5

CNGA1

2.3

CNIH3

1.9

CNKSR1

5.5

CNP

9.9

COG2

1.7

COPS2

6.1

COPS7B

1.5

COPS8

1.9

COQ2

1.8

COTL1

3.5

COX11

1.5

COX7A2

1.8

COX7B

1.5

CREB1

2.3

CREG1

clathrin interactor
1
ceroidlipofuscinosis,
neuronal 5
clathrin, light
polypeptide (Lca)
cyclic nucleotide
gated channel
alpha 1
cornichon homolog
3 (Drosophila)
connector enhancer
of kinase
suppressor of Ras
1
2',3'-cyclic
nucleotide 3'
phosphodiesterase
component of
oligomeric golgi
complex 2
COP9 constitutive
photomorphogenic
homolog subunit 2
(Arabidopsis)
COP9 constitutive
photomorphogenic
homolog subunit
7B (Arabidopsis)
COP9 constitutive
photomorphogenic
homolog subunit 8
(Arabidopsis)
coenzyme Q2
homolog,
prenyltransferase
(yeast)
coactosin-like 1
(Dictyostelium)
COX11 homolog,
cytochrome c
oxidase assembly
protein (yeast)
cytochrome c
oxidase subunit
VIIa polypeptide 2
(liver)
cytochrome c
oxidase subunit
VIIb
cAMP responsive
element binding
protein 1
cellular repressor
of E1A-stimulated

2.1

1.6

DCTD

dCMP deaminase

2.2

DCTN4

dynactin 4 (p62)

2.9

DCTN5

dynactin 5 (p25)

1.6

DDX19A

1.6

DDX28

3.1

DDX50

1.7

DENND2
D

3.1

DFFB

1.8

DHRS12

2.4

DHRS3

9.3

DIP

1.6

DKFZP5
64K0822

2.9

DMWD

2.1

DNAJB1
2

1.7

DNAJB9

2.1

DNAJC1
7

2

DNAJC8

1.9

DNAJC9

1.7

CTSB

cysteine-rich with
EGF-like domains
1
CREBBP/EP300
inhibitor 1
casein kinase 1,
alpha 1
C-terminal binding
protein 2
CTD (carboxyterminal domain,
RNA polymerase
II, polypeptide A)
small phosphatase
1
CTD (carboxyterminal domain,
RNA polymerase
II, polypeptide A)
small phosphatase
2
CTD (carboxyterminal domain,
RNA polymerase
II, polypeptide A)
small phosphataselike
centaurin, gammalike family,
member 1
cystathionase
(cystathionine
gamma-lyase)
cathepsin B

1.8

CTSS

cathepsin S

1.9

CXorf12

3.9

CXorf15

15.7

CRI1

1.5
6.2

CSNK1A
1
CTBP2

4.4

CTDSP1

2.5

CTDSP2

1.7

CTDSPL

2.4
6.5

5.5

	
  

CRELD1

genes 1

CTGLF1
CTH

CYB5B

2.5

CYB5R3

4.3

DBT

24.9

DCLRE1
B

chromosome X
open reading frame
12
chromosome X
open reading frame
15
cytochrome b5
type B (outer
mitochondrial
membrane)
cytochrome b5
reductase 3
dihydrolipoamide
branched chain
transacylase E2
DNA cross-link
repair 1B (PSO2
homolog, S.
cerevisiae)
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DEAD (Asp-GluAla-As) box
polypeptide 19A
DEAD (Asp-GluAla-Asp) box
polypeptide 28
DEAD (Asp-GluAla-Asp) box
polypeptide 50
DENN/MADD
domain containing
2D
DNA
fragmentation
factor, 40kDa, beta
polypeptide
(caspase-activated
DNase)
dehydrogenase/red
uctase (SDR
family) member 12
dehydrogenase/red
uctase (SDR
family) member 3
death-inducingprotein
hypothetical
protein
DKFZp564K0822
dystrophia
myotonicacontaining WD
repeat motif
DnaJ (Hsp40)
homolog,
subfamily B,
member 12
DnaJ (Hsp40)
homolog,
subfamily B,
member 9
DnaJ (Hsp40)
homolog,
subfamily C,
member 17
DnaJ (Hsp40)
homolog,
subfamily C,
member 8
DnaJ (Hsp40)
homolog,
subfamily C,

member 9
4.7

2.5

	
  

DR1

DSTN

4.4

DTX2

1.8

DUSP1

1.5

DYNLL1

1.8

DYNLT1

1.7

DYNLT3

7.1

E2F6

1.6

EBAG9

3.9

EEF1B2

1.5

EFCAB2

165.8

EFEMP2

3.2

EFNA4

1.8

EGFL9

3.7

EI24

1.7

EIF3S4

4

EIF5

1.7

EML2

2.3

EMP1

down-regulator of
transcription 1,
TBP-binding
(negative cofactor
2)
destrin (actin
depolymerizing
factor)
deltex homolog 2
(Drosophila)
dual specificity
phosphatase 1
dynein, light chain,
LC8-type 1
dynein, light chain,
Tctex-type 1
dynein, light chain,
Tctex-type 3
E2F transcription
factor 6
estrogen receptor
binding site
associated, antigen,
9
eukaryotic
translation
elongation factor 1
beta 2
EF-hand calcium
binding domain 2
EGF-containing
fibulin-like
extracellular
matrix protein 2
ephrin-A4
EGF-like-domain,
multiple 9
etoposide induced
2.4 mRNA
eukaryotic
translation
initiation factor 3,
subunit 4 delta,
44kDa
eukaryotic
translation
initiation factor 5
echinoderm
microtubule
associated protein
like 2
epithelial
membrane protein
1
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4.3

EMP2

1.6
5.3

ENDOG
L1
ENOSF1

1.7

ENOX1

3.3

ENSA

2.3

EPOR

1.9

ERCC8

12.5

ETF1

1.6

ETNK2

2.8

ETS2

3.2

ETV7

7

EXOC5

2.5

EXOSC2

3.1

F2RL1

1.5

FAF1

2.6

FAHD2A

1.7

FAM105
A

2.4

FAM131
A

4.7

FAM48A

epithelial
membrane protein
2
endonuclease Glike 1
enolase
superfamily
member 1
ecto-NOX
disulfide-thiol
exchanger 1
endosulfine alpha
erythropoietin
receptor
excision repair
crosscomplementing
rodent repair
deficiency,
complementation
group 8
eukaryotic
translation
termination factor
1
ethanolamine
kinase 2
v-ets
erythroblastosis
virus E26
oncogene homolog
2 (avian)
ets variant gene 7
(TEL2 oncogene)
exocyst complex
component 5
exosome
component 2
coagulation factor
II (thrombin)
receptor-like 1
Fas (TNFRSF6)
associated factor 1
fumarylacetoacetat
e hydrolase domain
containing 2A
family with
sequence similarity
105, member A
family with
sequence similarity
131, member A
family with
sequence similarity
48, member A

7.3

FAM57A

2.2

FAS

1.9

FASTK

2.1
1.8

	
  

FASTKD
5
FAU

family with
sequence similarity
57, member A
Fas (TNF receptor
superfamily,
member 6)
Fas-activated
serine/threonine
kinase
FAST kinase
domains 5
Finkel-BiskisReilly murine
sarcoma virus
(FBR-MuSV)
ubiquitously
expressed (fox
derived);
ribosomal protein
S30
fibrillarin

1.6

FBL

5

FBXL4

1.7

FBXO28

F-box and leucinerich repeat protein
4
F-box protein 28

1.7

FBXO9

F-box protein 9

2.2

FBXW11

1.6

FDFT1

1.5

FKBP2

1.7
1.8

FLJ2222
2
FN3KRP

1.5

FOXF2

2.3

FRAG1

1.5

FTH1

3.1

FTHP1

2.5

FTL

7.6

FUSIP1

F-box and WD-40
domain protein 11
farnesyldiphosphate
farnesyltransferase
1
FK506 binding
protein 2, 13kDa
hypothetical
protein FLJ22222
fructosamine-3kinase-related
protein
forkhead box F2
FGF receptor
activating protein 1
ferritin, heavy
polypeptide 1
ferritin, heavy
polypeptide
pseudogene 1
ferritin, light
polypeptide
FUS interacting
protein
(serine/argininerich) 1
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2.1

FZR1

2

G3BP2

12.8

GABAR
APL1

2.7

GAD1

1.9

GAS2L1

2.7

GAS6

3.2

GCDH

6.9

GDF11

1.5
1.5

GENX3414
GGA2

1.5

GGH

1.6

GGPS1

8.4

GGTL4

1.8

GHITM

1.8

GINS4

2.2

GLUD1

4

GM2A

1.6

GNAS

2.2

GNB1L

fizzy/cell division
cycle 20 related 1
(Drosophila)
GTPase activating
protein (SH3
domain) binding
protein 2
GABA(A)
receptor-associated
protein like 1
glutamate
decarboxylase 1
(brain, 67kDa)
growth arrestspecific 2 like 1
growth arrestspecific 6
glutaryl-Coenzyme
A dehydrogenase
growth
differentiation
factor 11
genethonin 1
golgi associated,
gamma adaptin ear
containing, ARF
binding protein 2
gamma-glutamyl
hydrolase
(conjugase,
folylpolygammagl
utamyl hydrolase)
geranylgeranyl
diphosphate
synthase 1
gammaglutamyltransferas
e-like 4
growth hormone
inducible
transmembrane
protein
GINS complex
subunit 4 (Sld5
homolog)
glutamate
dehydrogenase 1
GM2 ganglioside
activator
GNAS complex
locus
guanine nucleotide
binding protein (G
protein), beta
polypeptide 1-like

1.9

GPR110

1.9

GYG1

G protein-coupled
receptor 110
G protein-coupled
receptor 172A
G protein-coupled
receptor 30
glutathione
peroxidase 7
growth factor
receptor-bound
protein 10
G protein-coupled
receptor kinase 6
GrpE-like 1,
mitochondrial (E.
coli)
glycogen synthase
kinase 3 alpha
glycosyltransferase
-like domain
containing 1
general
transcription factor
IIH, polypeptide 2,
44kDa
general
transcription factor
IIIC, polypeptide
2, beta 110kDa
glycogenin 1

2.3
2.4

GPR172
A
GPR30

3

GPX7

2.7

GRB10

11.8

HCP5

HLA complex P5

1.7

HEMK1

5.3

HEXB

1.9

HIGD1A

1.6

HINT1

2.6

HIST1H1
E
HIST1H2
BD
HIST1H2
BK
HIST1H2
BM
HLA-F

HemK
methyltransferase
family member 1
hexosaminidase B
(beta polypeptide)
HIG1 domain
family, member
1A
histidine triad
nucleotide binding
protein 1
histone 1, H1e

1.7

GRK6

2

GRPEL1

3

GSK3A

4

GTDC1

1.6

1.9

1.7
2.1
1.8
39.4
1.5

	
  

GTF2H2

GTF3C2

HMOX1

2

HSBP1

1.5

HSD17B
7P2

2.4

HSF2BP

1.6

HSPA4

1.8

HSPBAP
1

1.9

HSPC111

3.4

HTATIP

1.9

IDH2

2.1

IDH3B

1.7

IDI1

1.6

IER3

1.6

IGFBP7

2.7

IIP45

2

IL11

2.1

IL11RA

4.1

IL13RA1

1.8

IL15

1.6

ING1

histone 1, H2bd

5.1

ING2

histone 1, H2bk

1.9

ING4

histone 1, H2bm

1.6

INSIG1

major
histocompatibility
complex, class I, F
heme oxygenase
(decycling) 1

5.4

IPO13

1.7

IQCC

6.4

IRX5
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heat shock factor
binding protein 1
hydroxysteroid
(17-beta)
dehydrogenase 7
pseudogene 2
heat shock
transcription factor
2 binding protein
heat shock 70kDa
protein 4
HSPB (heat shock
27kDa) associated
protein 1
hypothetical
protein HSPC111
HIV-1 Tat
interacting protein,
60kDa
isocitrate
dehydrogenase 2
(NADP+),
mitochondrial
isocitrate
dehydrogenase 3
(NAD+) beta
isopentenyldiphosphate delta
isomerase 1
immediate early
response 3
insulin-like growth
factor binding
protein 7
invasion inhibitory
protein 45
interleukin 11
interleukin 11
receptor, alpha
interleukin 13
receptor, alpha 1
interleukin 15
inhibitor of growth
family, member 1
inhibitor of growth
family, member 2
inhibitor of growth
family, member 4
insulin induced
gene 1
importin 13
IQ motif
containing C
iroquois homeobox
protein 5

2

ISG20L2

3.9

IVD

4.6

JOSD1

2.2

KATNA1

2.8

1.5

1.6

20.5

1.5

	
  

KCTD13

KCTD14

KDELR2

KDELR3

1.9

KIAA040
9
KIF22

1.5

KLF2

2

KLF4

29.4

KLF6

1.6

KPNA2

1.5

KPNA6

2.2

LANCL1

2.1

LARP6

interferon
stimulated
exonuclease gene
20kDa-like 2
isovaleryl
Coenzyme A
dehydrogenase
Josephin domain
containing 1
katanin p60
(ATPasecontaining) subunit
A1
potassium channel
tetramerisation
domain containing
13
potassium channel
tetramerisation
domain containing
14
KDEL (Lys-AspGlu-Leu)
endoplasmic
reticulum protein
retention receptor 2
KDEL (Lys-AspGlu-Leu)
endoplasmic
reticulum protein
retention receptor 3
KIAA0409

2.8

LASS2

63.1

LGALS1

1.6

LGALS8

1.6

LHFP

2.8

LITAF

2

LOC2601
0

2.1

1.9

LOC4412
94
LOC5410
3
LONRF3

3

LRRFIP2

2.1

LSM5

2.7

LYPLA1

1.7

LYRM1

2.3

MAFF

1.7

MANEA

1.8

MAP2K4

1.5

MAP2K5

2.3

MAP2K7

1.7

MAP3K7
IP2

1.9

kinesin family
member 22
Kruppel-like factor
2 (lung)
Kruppel-like factor
4 (gut)
Kruppel-like factor
6
karyopherin alpha
2 (RAG cohort 1,
importin alpha 1)
karyopherin alpha
6 (importin alpha
7)
LanC lantibiotic
synthetase
component C-like
1 (bacterial)
La
ribonucleoprotein
domain family,
member 6
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LAG1 longevity
assurance homolog
2 (S. cerevisiae)
lectin, galactosidebinding, soluble, 1
(galectin 1)
lectin, galactosidebinding, soluble, 8
(galectin 8)
lipoma HMGIC
fusion partner
lipopolysaccharide
-induced TNF
factor
viral DNA
polymerasetransactivated
protein 6
similar to
CTAGE6
hypothetical
protein LOC54103
LON peptidase Nterminal domain
and ring finger 3
leucine rich repeat
(in FLII)
interacting protein
2
LSM5 homolog,
U6 small nuclear
RNA associated
(S. cerevisiae)
lysophospholipase
I
LYR motif
containing 1
v-maf
musculoaponeuroti
c fibrosarcoma
oncogene homolog
F (avian)
mannosidase,
endo-alpha
mitogen-activated
protein kinase
kinase 4
mitogen-activated
protein kinase
kinase 5
mitogen-activated
protein kinase
kinase 7
mitogen-activated
protein kinase
kinase kinase 7

2.1

MAPK12

1.5

MAPKA
PK2

1.5

MBD1

1.5

MBIP

1.7

MCFP

1.5

MCOLN
1
MCP

2.1

1.5
10.4

2

3.3
2.8

5.3

	
  

MDH1
ME2

ME3

MECP2
MED18

MED9

2.4

MEST

1.7

METTL2

1.5

MFN2

1.7

MFSD5

interacting protein
2
mitogen-activated
protein kinase 12
mitogen-activated
protein kinaseactivated protein
kinase 2
methyl-CpG
binding domain
protein 1
MAP3K12 binding
inhibitory protein 1
mitochondrial
carrier family
protein
mucolipin 1
membrane cofactor
protein (CD46,
trophoblastlymphocyte crossreactive antigen)
malate
dehydrogenase 1,
NAD (soluble)
malic enzyme 2,
NAD(+)dependent,
mitochondrial
malic enzyme 3,
NADP(+)dependent,
mitochondrial
methyl CpG
binding protein 2
(Rett syndrome)
mediator of RNA
polymerase II
transcription,
subunit 18
homolog (yeast)
mediator of RNA
polymerase II
transcription,
subunit 9 homolog
(yeast)
mesoderm specific
transcript homolog
(mouse)
methyltransferase
like 2
mitofusin 2
major facilitator
superfamily
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1.6

MGC143
76

1.9
1.5

MGC275
2
MGST2

1.5

MICA

2.2

MID1IP1

2.3

MIS12

1.6

MKNK2

1.5

MLL4

1.9

MLX

1.9

MLYCD

1.7

MMD

1.5

MMP14

23

MMP9

2.7

MPZL1

11.4

MR1

1.5

MRPL3

2.1

MRPL9

domain containing
5
hypothetical
protein
MGC14376
hypothetical
protein MGC2752
microsomal
glutathione Stransferase 2
MHC class I
polypeptide-related
sequence A
MID1 interacting
protein 1
(gastrulation
specific G12-like
(zebrafish))
MIS12 homolog
(yeast)
MAP kinase
interacting
serine/threonine
kinase 2
myeloid/lymphoid
or mixed-lineage
leukemia 4
MAX-like protein
X
malonyl-CoA
decarboxylase
monocyte to
macrophage
differentiationassociated
matrix
metallopeptidase
14 (membraneinserted)
matrix
metallopeptidase 9
(gelatinase B,
92kDa gelatinase,
92kDa type IV
collagenase)
myelin protein
zero-like 1
major
histocompatibility
complex, class Irelated
mitochondrial
ribosomal protein
L3
mitochondrial
ribosomal protein

L9
1.5

MRPS10

2.8

MT1H

mitochondrial
ribosomal protein
S10
mitochondrial
ribosomal protein
S12
MRS2-like,
magnesium
homeostasis factor
(S. cerevisiae)
metallothionein 1H

1.7

MRPS12

40.7

MT1X

metallothionein 1X

1.7

MTA1

3.7

MTHFD2
L

2.5

3.6

MYNN

metastasis
associated 1
methylenetetrahydr
ofolate
dehydrogenase
(NADP+
dependent) 2-like
mitochondrial
translation
optimization 1
homolog (S.
cerevisiae)
5methyltetrahydrofo
late-homocysteine
methyltransferase
reductase
mevalonate kinase
(mevalonic
aciduria)
matrix-remodelling
associated 7
c-myc binding
protein
myeloid
differentiation
primary response
gene (88)
myosin, light
polypeptide 4,
alkali; atrial,
embryonic
myoneurin

2.3

MYO9B

myosin IXB

1.8

MYOHD
1

myosin head
domain containing
1
MYST histone
acetyltransferase 1
similar to 60S
ribosomal protein

2.8

1.9

	
  

MRS2L

MTO1

MTRR

1.5

MVK

4.4

MXRA7

1.6

MYCBP

1.9

MYD88

2.3

MYL4

2.4

MYST1

8.9

na

L13 (A52)
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2.2

NAB1

1.7

NADK

1.8

NAPG

1.5

NDUFA5

3.6

NEK11

1.5

NEK2

1.5

NFYC

2.1

NGFRAP
1

1.9

NGRN

1.8
2.5

NIPSNA
P1
NMD3

1.8

NMT1

3.4

NMT2

2.1

NOSIP

1.5

NPAS2

6.8

NSDHL

2.1

NSMAF

4

OAZ1

NGFI-A binding
protein 1 (EGR1
binding protein 1)
NAD kinase
N-ethylmaleimidesensitive factor
attachment protein,
gamma
NADH
dehydrogenase
(ubiquinone) 1
alpha subcomplex,
5, 13kDa
NIMA (never in
mitosis gene a)related kinase 11
NIMA (never in
mitosis gene a)related kinase 2
nuclear
transcription factor
Y, gamma
nerve growth
factor receptor
(TNFRSF16)
associated protein
1
neugrin, neurite
outgrowth
associated
nipsnap homolog 1
(C. elegans)
NMD3 homolog
(S. cerevisiae)
Nmyristoyltransferas
e1
Nmyristoyltransferas
e2
nitric oxide
synthase
interacting protein
neuronal PAS
domain protein 2
NAD(P) dependent
steroid
dehydrogenase-like
neutral
sphingomyelinase
(N-SMase)
activation
associated factor
ornithine

1.5

	
  

OR7E47
P

1.8

ORC4L

1.6

OTUB1

1.8

P2RX5

12.7

P2RY2

1.6

PABPN1

1.5

PAIP1

1.8

PAOX

2.2

PAX8

1.5

PBX2

4

PCGF2

1.8

PCLO

2.9

PCOLCE
2

2.1

PCTP

9

PCYT1A

2.9

PDCD2

1.6

PDE10A

1.9

PDS5A

2.1

PEX16

decarboxylase
antizyme 1
olfactory receptor,
family 7,
subfamily E,
member 47
pseudogene
origin recognition
complex, subunit
4-like (yeast)
OTU domain,
ubiquitin aldehyde
binding 1
purinergic receptor
P2X, ligand-gated
ion channel, 5
purinergic receptor
P2Y, G-protein
coupled, 2
poly(A) binding
protein, nuclear 1
poly(A) binding
protein interacting
protein 1
polyamine oxidase
(exo-N4-amino)
paired box gene 8
pre-B-cell
leukemia
transcription factor
2
polycomb group
ring finger 2
piccolo
(presynaptic
cytomatrix protein)
procollagen Cendopeptidase
enhancer 2
phosphatidylcholin
e transfer protein
phosphate
cytidylyltransferas
e 1, choline, alpha
programmed cell
death 2
phosphodiesterase
10A
PDS5, regulator of
cohesion
maintenance,
homolog A (S.
cerevisiae)
peroxisomal
biogenesis factor
16
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1.7

PEX3

2.4

PFKL

1.7

PGF

6.7

PGGT1B

1.5

PHB

1.5

PHF1

1.9

PHF2

1.6

PHTF1

15.2

PHTF2

3.3

PIAS2

7.7

PIGB

2.5

PIK4CB

1.8

PIM2

2.3

PIP5K1A

2

PKNOX1

2.9

PLA2G4
B

3.3

PLAC1

1.5

PLAUR

1.5

PLEKH
M2

1.6

PLSCR3

peroxisomal
biogenesis factor 3
phosphofructokina
se, liver
placental growth
factor, vascular
endothelial growth
factor-related
protein
protein
geranylgeranyltran
sferase type I, beta
subunit
prohibitin
PHD finger protein
1
PHD finger protein
2
putative
homeodomain
transcription factor
1
putative
homeodomain
transcription factor
2
protein inhibitor of
activated STAT, 2
phosphatidylinosit
ol glycan, class B
phosphatidylinosit
ol 4-kinase,
catalytic, beta
polypeptide
pim-2 oncogene
phosphatidylinosit
ol-4-phosphate 5kinase, type I,
alpha
PBX/knotted 1
homeobox 1
phospholipase A2,
group IVB
(cytosolic)
placenta-specific 1
plasminogen
activator,
urokinase receptor
pleckstrin
homology domain
containing, family
M (with RUN
domain) member 2
phospholipid
scramblase 3

2.1

PMAIP1

18.4

PMP22

1.9

PMS2L3

1.6

PMS2L5

4.8

POLA2

2

POLDIP2

6.2

9.4

POLE3

1.6

PON3

2.7

POT1

1.6

PPA1

2.3

PPFIA1

2.8

PPIA

1.6

PPID

2.5

PPP1R7

4.8

	
  

POLDIP3

PPP2R1B

phorbol-12myristate-13acetate-induced
protein 1
peripheral myelin
protein 22
postmeiotic
segregation
increased 2-like 3
postmeiotic
segregation
increased 2-like 5
polymerase (DNA
directed), alpha 2
(70kD subunit)
polymerase (DNAdirected), delta
interacting protein
2
polymerase (DNAdirected), delta
interacting protein
3
polymerase (DNA
directed), epsilon 3
(p17 subunit)
paraoxonase 3
POT1 protection of
telomeres 1
homolog (S.
pombe)
pyrophosphatase
(inorganic) 1
protein tyrosine
phosphatase,
receptor type, f
polypeptide
(PTPRF),
interacting protein
(liprin), alpha 1
peptidylprolyl
isomerase A
(cyclophilin A)
peptidylprolyl
isomerase D
(cyclophilin D)
protein
phosphatase 1,
regulatory subunit
7
protein
phosphatase 2
(formerly 2A),
regulatory subunit
A (PR 65), beta
isoform
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10

PPP3R1

2.2

PPT2

1.8

PRG1

1.5

PRKAB1

2.4

PRKD3

4.3

PRKRIP1

2.2

PRPF4

5.6

PRSS23

1.5

PRUNE

12.4

PSKH1

1.8

PSMA1

1.5

PSMA7

5.5

PSMB4

1.6

PSMC5

2

PSMD4

1.7

PSME1

protein
phosphatase 3
(formerly 2B),
regulatory subunit
B, 19kDa, alpha
isoform
(calcineurin B,
type I)
palmitoyl-protein
thioesterase 2
proteoglycan 1,
secretory granule
protein kinase,
AMP-activated,
beta 1 noncatalytic subunit
protein kinase D3
PRKR interacting
protein 1 (IL11
inducible)
PRP4 pre-mRNA
processing factor 4
homolog (yeast)
protease, serine, 23
prune homolog
(Drosophila)
protein serine
kinase H1
proteasome
(prosome,
macropain)
subunit, alpha type,
1
proteasome
(prosome,
macropain)
subunit, alpha type,
7
proteasome
(prosome,
macropain)
subunit, beta type,
4
proteasome
(prosome,
macropain) 26S
subunit, ATPase, 5
proteasome
(prosome,
macropain) 26S
subunit, nonATPase, 4
proteasome
(prosome,
macropain)

2

PTP4A1

1.6

PTPLAD
1

7.1

PTPN11

11.7

PTPN2

1.6

PTPN3

1.6

PTPN9

3.9

PTPRA

1.7

PTTG1

7.8

QKI

1.9

RAB2

2.9

RAB23

8.8

RABEP1

2

RABL2B

1.8

RAC3

1.5

RAD17

1.8

RAD51

1.7

	
  

RAD51A
P1

activator subunit 1
(PA28 alpha)
protein tyrosine
phosphatase type
IVA, member 1
protein tyrosine
phosphatase-like A
domain containing
1
protein tyrosine
phosphatase, nonreceptor type 11
(Noonan syndrome
1)
protein tyrosine
phosphatase, nonreceptor type 2
protein tyrosine
phosphatase, nonreceptor type 3
protein tyrosine
phosphatase, nonreceptor type 9
protein tyrosine
phosphatase,
receptor type, A
pituitary tumortransforming 1
quaking homolog,
KH domain RNA
binding (mouse)
RAB2, member
RAS oncogene
family
RAB23, member
RAS oncogene
family
rabaptin, RAB
GTPase binding
effector protein 1
RAB, member of
RAS oncogene
family-like 2B
ras-related C3
botulinum toxin
substrate 3 (rho
family, small GTP
binding protein
Rac3)
RAD17 homolog
(S. pombe)
RAD51 homolog
(RecA homolog, E.
coli) (S. cerevisiae)
RAD51 associated
protein 1
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1.9

RAD9A

1.7

RALA

6.5

RANBP3

1.7
2.2

RANGA
P1
RBMS2

1.7

RBMX2

1.5

RCL1

3.7

RCP9

2.3

RGS19

1.5

RHEB

2.4

RHOA

7

RHOBT
B3

1.8

RHOT1

1.6

RHOT2

1.6

RIPK2

2

RNF146

1.5

RNF41

1.9

RNPEPL
1

3.2

RPA1

2.4

RPL13

2.4

RPL18

2.6

RPL35

RAD9 homolog A
(S. pombe)
v-ral simian
leukemia viral
oncogene homolog
A (ras related)
RAN binding
protein 3
Ran GTPase
activating protein 1
RNA binding
motif, single
stranded
interacting protein
2
RNA binding motif
protein, X-linked 2
RNA terminal
phosphate cyclaselike 1
Calcitonin generelated peptidereceptor
component protein
regulator of Gprotein signalling
19
Ras homolog
enriched in brain
ras homolog gene
family, member A
Rho-related BTB
domain containing
3
ras homolog gene
family, member T1
ras homolog gene
family, member T2
receptorinteracting serinethreonine kinase 2
ring finger protein
146
ring finger protein
41
arginyl
aminopeptidase
(aminopeptidase
B)-like 1
replication protein
A1, 70kDa
ribosomal protein
L13
ribosomal protein
L18
ribosomal protein

L35
18.5

RPL35A

1.7

RPS10

2

RPS14

1.9

RPS20

3

RPS6KA
4

1.5

RPS6KB
1

4.5

RRAGD

1.5

RRM2

1.9

RRP15

2

1.7

RSU1

1.5

RY1

1.9

2

	
  

RRS1

S100A10

S100A4

3.1

SAP30

170.9

SAPS2

2.3

SCARB2

2

SCMH1

ribosomal protein
L35a
ribosomal protein
S10
ribosomal protein
S14
ribosomal protein
S20
ribosomal protein
S6 kinase, 90kDa,
polypeptide 4
ribosomal protein
S6 kinase, 70kDa,
polypeptide 1
Ras-related GTP
binding D
ribonucleotide
reductase M2
polypeptide
ribosomal RNA
processing 15
homolog (S.
cerevisiae)
RRS1 ribosome
biogenesis
regulator homolog
(S. cerevisiae)
Ras suppressor
protein 1
putative nucleic
acid binding
protein RY-1
S100 calcium
binding protein
A10 (annexin II
ligand, calpactin I,
light polypeptide
(p11))
S100 calcium
binding protein A4
(calcium protein,
calvasculin,
metastasin, murine
placental homolog)
sin3-associated
polypeptide,
30kDa
SAPS domain
family, member 2
scavenger receptor
class B, member 2
sex comb on
midleg homolog 1
(Drosophila)
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2.5

SCPEP1

1.5

SDAD1

2.1

SDCCA
G3

4.8

SEC22L1

15.1

SEC23A

1.6
1.8

SECISBP
2
SECTM1

1.5

SENP2

6.7

SEPHS1

2.2

SERGEF

1.5

SET

1.6

SETDB1

2.5

SF4

1.9

SH2D3A

15.6

SIAH1

1.6

SIP1

19.4

SIRT3

2.2

SIX2

1.8

SLC12A
9

serine
carboxypeptidase 1
SDA1 domain
containing 1
serologically
defined colon
cancer antigen 3
SEC22 vesicle
trafficking proteinlike 1 (S.
cerevisiae)
Sec23 homolog A
(S. cerevisiae)
SECIS binding
protein 2
secreted and
transmembrane 1
SUMO1/sentrin/S
MT3 specific
peptidase 2
selenophosphate
synthetase 1
secretion
regulating guanine
nucleotide
exchange factor
SET translocation
(myeloid
leukemiaassociated)
SET domain,
bifurcated 1
splicing factor 4
SH2 domain
containing 3A
seven in absentia
homolog 1
(Drosophila)
survival of motor
neuron protein
interacting protein
1
sirtuin (silent
mating type
information
regulation 2
homolog) 3 (S.
cerevisiae)
sine oculis
homeobox
homolog 2
(Drosophila)
solute carrier
family 12
(potassium/chlorid
e transporters),

member 9
2.9

1.6

7.2

SLC25A
14

SLC25A
5

2

SLC31A
1

2

SLC31A
2

1.6

SLC35A
2

1.5

SLC35C2

3.5

SLC35F2

1.5

SLC38A
6

1.5

SLC39A
6

3.9

SLC39A
8

2
1.8

	
  

SLC22A
14

SLC41A
3
SLC43A
1

solute carrier
family 22 (organic
cation transporter),
member 14
solute carrier
family 25
(mitochondrial
carrier, brain),
member 14
solute carrier
family 25
(mitochondrial
carrier; adenine
nucleotide
translocator),
member 5
solute carrier
family 31 (copper
transporters),
member 1
solute carrier
family 31 (copper
transporters),
member 2
solute carrier
family 35 (UDPgalactose
transporter),
member A2
solute carrier
family 35, member
C2
solute carrier
family 35, member
F2
solute carrier
family 38, member
6
solute carrier
family 39 (zinc
transporter),
member 6
solute carrier
family 39 (zinc
transporter),
member 8
solute carrier
family 41, member
3
solute carrier
family 43, member
1
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28.4

SLCO1B
3

1.5

SMAD2

3.5

SMARC
D2

1.5

SMN1

1.5

SNAI2

2.2

SNRPD1

2.8

SNRPE

1.5

SNRPF

1.6

SNRPG

2.4

SOCS2

2.1

SOD1

2.3

SORBS3

59.9

SORT1

1.8

SPCS3

2.6

SPHK1

26.2

SPOP

32.5

SPRY4

solute carrier
organic anion
transporter family,
member 1B3
SMAD, mothers
against DPP
homolog 2
(Drosophila)
SWI/SNF related,
matrix associated,
actin dependent
regulator of
chromatin,
subfamily d,
member 2
survival of motor
neuron 1, telomeric
snail homolog 2
(Drosophila)
small nuclear
ribonucleoprotein
D1 polypeptide
16kDa
small nuclear
ribonucleoprotein
polypeptide E
small nuclear
ribonucleoprotein
polypeptide F
small nuclear
ribonucleoprotein
polypeptide G
suppressor of
cytokine signaling
2
superoxide
dismutase 1,
soluble
(amyotrophic
lateral sclerosis 1
(adult))
sorbin and SH3
domain containing
3
sortilin 1
signal peptidase
complex subunit 3
homolog (S.
cerevisiae)
sphingosine kinase
1
speckle-type POZ
protein
sprouty homolog 4
(Drosophila)

4.2

9

SREBF2

2.1

SRI

1.5

SRP72

1.7

SRPK1

58.5

SRPRB

2.4

SS18

14.9

SSBP3

steroid-5-alphareductase, alpha
polypeptide 1 (3oxo-5 alpha-steroid
delta 4dehydrogenase
alpha 1)
sterol regulatory
element binding
transcription factor
2
sorcin

1.6

TANK

2.5

TAX1BP
3

2.2

TBC1D2
2A

3.1

TBC1D8

1.5

TCEAL1

2.3

TCFL5

2.6

TCP11L1

1.5

TEGT

3.2

TENC1

2.9

TFAM

9.5

TFCP2

1.7

STK11

9.1

STK6

12.5

STOM

signal recognition
particle 72kDa
SFRS protein
kinase 1
signal recognition
particle receptor, B
subunit
synovial sarcoma
translocation,
chromosome 18
single stranded
DNA binding
protein 3
signal transducer
and activator of
transcription 1,
91kDa
serine/threonine
kinase 11 (PeutzJeghers syndrome)
serine/threonine
kinase 6
stomatin

10.7

STX18

syntaxin 18

1.5

TFDP1

1.5

SULT1A
1

7.9

TFDP2

7.9

SULT1A
3

5.1

TFPI

1.8

SUMO3

1.7

TGDS

3.7

SYPL1

8.3

THAP10

1.9

TAF6

sulfotransferase
family, cytosolic,
1A, phenolpreferring, member
1
sulfotransferase
family, cytosolic,
1A, phenolpreferring, member
3
SMT3 suppressor
of mif two 3
homolog 3 (yeast)
synaptophysin-like
1
TAF6 RNA
polymerase II,
TATA box binding
protein (TBP)-

1.6

THG1L

1.9

	
  

SRD5A1

STAT1
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associated factor,
80kDa
TRAF family
member-associated
NFKB activator
Tax1 (human Tcell leukemia virus
type I) binding
protein 3
TBC1 domain
family, member
22A
TBC1 domain
family, member 8
(with GRAM
domain)
transcription
elongation factor A
(SII)-like 1
transcription
factor-like 5 (basic
helix-loop-helix)
t-complex 11
(mouse) like 1
testis enhanced
gene transcript
(BAX inhibitor 1)
tensin like C1
domain containing
phosphatase
(tensin 2)
transcription factor
A, mitochondrial
transcription factor
CP2
transcription factor
Dp-1
transcription factor
Dp-2 (E2F
dimerization
partner 2)
tissue factor
pathway inhibitor
(lipoproteinassociated
coagulation
inhibitor)
TDP-glucose 4,6dehydratase
THAP domain
containing 10
tRNA-histidine
guanylyltransferase
1-like (S.
cerevisiae)

2.5

3.4

TIMM17
A

1.5

TINF2

4.2

TK2

1.9

TMBIM4

1.5
1.5

TMCO1
TMED9

1.9

TMPO

TIA1 cytotoxic
granule-associated
RNA binding
protein
translocase of inner
mitochondrial
membrane 17
homolog A (yeast)
TERF1 (TRF1)interacting nuclear
factor 2
thymidine kinase
2, mitochondrial
transmembrane
BAX inhibitor
motif containing 4
transmembrane
and coiled-coil
domains 1
transmembrane
emp24 protein
transport domain
containing 9
thymopoietin

9

TMSB10

thymosin, beta 10

13218.
9

TNFRSF
11B

1.8

TNFRSF
14

tumor necrosis
factor receptor
superfamily,
member 11b
(osteoprotegerin)
tumor necrosis
factor receptor
superfamily,
member 14
(herpesvirus entry
mediator)
tumor necrosis
factor (ligand)
superfamily,
member 10
tumor necrosis
factor (ligand)
superfamily,
member 13
tumor necrosis
factor (ligand)
superfamily,
member 9
torsin family 1,
member A (torsin
A)
torsin A interacting
protein 1
TP53 activated
protein 1

2.6

TNFSF10

2

TNFSF13

2.3

TNFSF9

3.7

TOR1A

2.6

TOR1AI
P1
TP53AP1

3.5

	
  

TIA1

2

TPD52

tumor protein D52

3.2

TPM4

tropomyosin 4

1.5

TRAM1

2.2

2.7

TRAPPC
2
TRAPPC
4
TRBC1

2.5

TRIM68

2.7

TSPAN3

translocation
associated
membrane protein
1
trafficking protein
particle complex 2
trafficking protein
particle complex 4
T cell receptor beta
constant 1
tripartite motifcontaining 68
tetraspanin 3

5.2

TSPAN9

tetraspanin 9

3.8

TTC19

1.8

TXNL2

10.6

UBA52

1.8

UBAP1

1.5

UBE2D3

4.5

UBE2G1

2.8

UBE2J1

4.4

UBE2L3

1.5

UBE2L6

1.5

UBE2N

2.5

UBE2V1

1.9
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tetratricopeptide
repeat domain 19
thioredoxin-like 2
ubiquitin A-52
residue ribosomal
protein fusion
product 1
ubiquitin
associated protein
1
ubiquitinconjugating
enzyme E2D 3
(UBC4/5 homolog,
yeast)
ubiquitinconjugating
enzyme E2G 1
(UBC7 homolog,
yeast)
ubiquitinconjugating
enzyme E2, J1
(UBC6 homolog,
yeast)
ubiquitinconjugating
enzyme E2L 3
ubiquitinconjugating
enzyme E2L 6
ubiquitinconjugating
enzyme E2N
(UBC13 homolog,
yeast)
ubiquitinconjugating

	
  

2.3

UBE2V2

1.5

UBE3B

3.5

UBL3

1.9

UBXD6

1.7
1.7

UCHL5I
P
UFC1

3.5

UNG2

2.4

USP3

1.7

VBP1

8.5

VEGF

1.6

VGF

6.4

VPS37C

1.6

VRK3

3.2

WASPIP

13.8

WBP5

1.7

WDR23

5.8

WDR62

1.9

WHSC1

6.1

WIPI2

2.1

WSB2

3.6

XAB1

2.1

XAF1

enzyme E2 variant
1
ubiquitinconjugating
enzyme E2 variant
2
ubiquitin protein
ligase E3B
ubiquitin-like 3
UBX domain
containing 6
UCHL5 interacting
protein
ubiquitin-fold
modifier
conjugating
enzyme 1
uracil-DNA
glycosylase 2
ubiquitin specific
peptidase 3
von Hippel-Lindau
binding protein 1
vascular
endothelial growth
factor
VGF nerve growth
factor inducible
vacuolar protein
sorting 37C (yeast)
vaccinia related
kinase 3
Wiskott-Aldrich
syndrome protein
interacting protein
WW domain
binding protein 5
WD repeat domain
23
WD repeat domain
62
Wolf-Hirschhorn
syndrome
candidate 1
WD repeat
domain,
phosphoinositide
interacting 2
WD repeat and
SOCS boxcontaining 2
XPA binding
protein 1, GTPase
XIAP associated
factor-1

7.9

YWHAQ

3.4

ZC3H14

1.5

ZDHHC6

1.7

ZFP36

6.3

ZNF133

1.7

ZNF143

1.5

ZNF22

3.6

ZNF232

1.7

ZNF239

1.5

ZNF277

2.7

ZNF278

27

ZNF34

4.5

ZNF410

13

ZNF435

57.8

ZNF45

4.2

ZNF473

8.3

ZNF673

25

ZNF768

2

ZNF9

1.6

ZSCAN5

Not
Bound
to
Bound
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tyrosine 3monooxygenase/tr
yptophan 5monooxygenase
activation protein,
theta polypeptide
zinc finger CCCHtype containing 14
zinc finger,
DHHC-type
containing 6
zinc finger protein
36, C3H type,
homolog (mouse)
zinc finger protein
133 (clone pHZ13)
zinc finger protein
143 (clone pHZ-1)
zinc finger protein
22 (KOX 15)
zinc finger protein
232
zinc finger protein
239
zinc finger protein
277
zinc finger protein
278
zinc finger protein
34 (KOX 32)
zinc finger protein
410
zinc finger protein
435
zinc finger protein
45
zinc finger protein
473
zinc finger protein
673
zinc finger protein
768
zinc finger protein
9 (a cellular
retroviral nucleic
acid binding
protein)
zinc finger and
SCAN domain
containing 5

ASTE1
AASDHP
PT

ABCA2

ACVR1
ADAM1
0
ADH5

AGA
AK2
ALDH1B
1

ANGPT1

aldehyde
dehydrogenase 1
family, member B1
aldehyde
dehydrogenase 3
family, member
A2
Alstrom syndrome
1
adenosylmethionin
e decarboxylase 1
angiopoietin 1

ANKRD
49
APOL2

ankyrin repeat
domain 49
apolipoprotein L, 2

APS

adaptor protein
with pleckstrin
homology and src
homology 2
domains
ariadne homolog 2
(Drosophila)
ADP-ribosylation
factor-like 8B
aryl hydrocarbon
receptor nuclear
translocator-like 2
arylsulfatase B

ALDH3A
2
ALMS1
AMD1

ARIH2
ARL8B
ARNTL2
ARSB
ASF1A

	
  

aminoadipatesemialdehyde
dehydrogenasephosphopantethein
yl transferase
ATP-binding
cassette, subfamily A (ABC1),
member 2
activin A receptor,
type I
ADAM
metallopeptidase
domain 10
alcohol
dehydrogenase 5
(class III), chi
polypeptide
aspartylglucosamin
idase
adenylate kinase 2

B2M
B4GALT
1

BAIAP2
BECN1

BFSP1
BNIP3L

BRD2
BRD9
BRMS1
BSDC1
BTF3
BTN3A3
BUB1

BZW1
C14orf11
8
C15orf39
C16orf34

ASF1 antisilencing function
1 homolog A (S.
cerevisiae)

C16orf5
C17orf70
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asteroid homolog 1
(Drosophila)
beta-2microglobulin
UDPGal:betaGlcNAc
beta 1,4galactosyltransfera
se, polypeptide 1
BAI1-associated
protein 2
beclin 1 (coiledcoil, myosin-like
BCL2 interacting
protein)
beaded filament
structural protein
1, filensin
BCL2/adenovirus
E1B 19kDa
interacting protein
3-like
bromodomain
containing 2
bromodomain
containing 9
breast cancer
metastasis
suppressor 1
BSD domain
containing 1
basic transcription
factor 3
butyrophilin,
subfamily 3,
member A3
BUB1 budding
uninhibited by
benzimidazoles 1
homolog (yeast)
basic leucine
zipper and W2
domains 1
chromosome 14
open reading frame
118
chromosome 15
open reading frame
39
chromosome 16
open reading frame
34
chromosome 16
open reading frame
5
chromosome 17

C1orf108
C1orf121
C1orf166
C1QDC1
C20orf18
C20orf3
C21orf55
C2orf24
C2orf56
C4orf16
C6orf62
C6orf68
C7orf25
C8orf41
CANT1
CASP10
CBX3

CCDC59
CCNG2

	
  

open reading frame
70
chromosome 1
open reading frame
108
chromosome 1
open reading frame
121
chromosome 1
open reading frame
166
C1q domain
containing 1
chromosome 20
open reading frame
18
chromosome 20
open reading frame
3
chromosome 21
open reading frame
55
chromosome 2
open reading frame
24
chromosome 2
open reading frame
56
chromosome 4
open reading frame
16
chromosome 6
open reading frame
62
chromosome 6
open reading frame
68
chromosome 7
open reading frame
25
chromosome 8
open reading frame
41
calcium activated
nucleotidase 1
caspase 10,
apoptosis-related
cysteine peptidase
chromobox
homolog 3 (HP1
gamma homolog,
Drosophila)
coiled-coil domain
containing 59
cyclin G2

CCNJ
CCNT2

cyclin T2

CDCA8

cell division cycle
associated 8
cadherin 11, type
2, OB-cadherin
(osteoblast)
cyclin-dependent
kinase (CDC2like) 10
CDK5 regulatory
subunit associated
protein 1-like 1
CDPdiacylglycerol
synthase
(phosphatidate
cytidylyltransferas
e) 2
CDV3 homolog
(mouse)
ceramide kinase

CDH11
CDK10
CDKAL1
CDS2

CDV3
CERK
CES2
CFLAR
CH25H
CHCHD3

CHST4

CLK1
CLN8

COG5
COL1A1
COX15

CRBN
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cyclin J

carboxylesterase 2
(intestine, liver)
CASP8 and
FADD-like
apoptosis regulator
cholesterol 25hydroxylase
coiled-coil-helixcoiled-coil-helix
domain containing
3
carbohydrate (Nacetylglucosamine
6-O)
sulfotransferase 4
CDC-like kinase 1
ceroidlipofuscinosis,
neuronal 8
(epilepsy,
progressive with
mental retardation)
component of
oligomeric golgi
complex 5
collagen, type I,
alpha 1
COX15 homolog,
cytochrome c
oxidase assembly
protein (yeast)
cereblon

CREM

CTSO

cAMP responsive
element modulator
v-crk sarcoma
virus CT10
oncogene homolog
(avian)-like
chondroitin sulfate
glucuronyltransfera
se
casein kinase 1,
epsilon
CTAGE family,
member 5
C-terminal binding
protein 1
cathepsin O

CUL1

cullin 1

CRKL

CSGlcAT
CSNK1E
CTAGE5
CTBP1

CXorf34
CXorf45
CYB561
CYP26B
1
CYP2R1

CYP51A
1
DARS2
DBF4
DCUN1
D2

DCUN1
D4

DDX17
DHODH

	
  

dehydrogenase
DHRS7
DKFZP5
64O0523
DLG1
DLX4
DNAJB4

DNAJC1
0

chromosome X
open reading frame
34
chromosome X
open reading frame
45
cytochrome b-561

DRAM
DYRK3

cytochrome P450,
family 26,
subfamily B,
polypeptide 1
cytochrome P450,
family 2,
subfamily R,
polypeptide 1
cytochrome P450,
family 51,
subfamily A,
polypeptide 1
aspartyl-tRNA
synthetase 2
(mitochondrial)
DBF4 homolog (S.
cerevisiae)
DCN1, defective in
cullin neddylation
1, domain
containing 2 (S.
cerevisiae)
DCN1, defective in
cullin neddylation
1, domain
containing 4 (S.
cerevisiae)
DEAD (Asp-GluAla-Asp) box
polypeptide 17
dihydroorotate

ECHDC1
EDIL3
EGFR
EIF2AK1

EIF4E2

ELAVL1

EPB41L4
B
EPN2
ETFDH
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dehydrogenase/red
uctase (SDR
family) member 7
hypothetical
protein
DKFZp564O0523
discs, large
homolog 1
(Drosophila)
distal-less
homeobox 4
DnaJ (Hsp40)
homolog,
subfamily B,
member 4
DnaJ (Hsp40)
homolog,
subfamily C,
member 10
damage-regulated
autophagy
modulator
dual-specificity
tyrosine-(Y)phosphorylation
regulated kinase 3
enoyl Coenzyme A
hydratase domain
containing 1
EGF-like repeats
and discoidin I-like
domains 3
Epidermal growth
factor receptor
(EGFR)
eukaryotic
translation
initiation factor 2alpha kinase 1
eukaryotic
translation
initiation factor 4E
family member 2
ELAV (embryonic
lethal, abnormal
vision,
Drosophila)-like 1
(Hu antigen R)
erythrocyte
membrane protein
band 4.1 like 4B
epsin 2
electrontransferring-

flavoprotein
dehydrogenase
EVA1
EXOC7
EXTL2
EXTL3
FAIM
FAM32A
FAM46C
FAM69A
FANCC
FARP1

FBXL2
FBXL5
FEZ2
FKBP14
FLJ1118
4
FNBP3
FOXK2
FRAT1

FZD6
G6PC3

	
  

catalytic, 3
GALNT1

epithelial V-like
antigen 1
exocyst complex
component 7
exostoses
(multiple)-like 2
exostoses
(multiple)-like 3
Fas apoptotic
inhibitory
molecule
family with
sequence similarity
32, member A
family with
sequence similarity
46, member C
Family with
sequence similarity
69, member A
Fanconi anemia,
complementation
group C
FERM, RhoGEF
(ARHGEF) and
pleckstrin domain
protein 1
(chondrocytederived)
F-box and leucinerich repeat protein
2
F-box and leucinerich repeat protein
5
fasciculation and
elongation protein
zeta 2 (zygin II)
FK506 binding
protein 14, 22 kDa
hypothetical
protein FLJ11184
formin binding
protein 3
forkhead box K2

GAPDH
GCAT

GCLC
GCNT1

GDAP2

GLB1L
GLMN
GLO1
GMFB
GNA11

GNL1
GOLGA1

frequently
rearranged in
advanced T-cell
lymphomas
frizzled homolog 6
(Drosophila)
glucose 6
phosphatase,

GRB2
GTF2F2
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UDP-N-acetylalpha-Dgalactosamine:poly
peptide Nacetylgalactosamin
yltransferase 1
(GalNAc-T1)
glyceraldehyde-3phosphate
dehydrogenase
glycine Cacetyltransferase
(2-amino-3ketobutyrate
coenzyme A
ligase)
glutamate-cysteine
ligase, catalytic
subunit
glucosaminyl (Nacetyl) transferase
1, core 2 (beta-1,6Nacetylglucosaminyl
transferase)
ganglioside
induced
differentiation
associated protein
2
galactosidase, beta
1-like
glomulin, FKBP
associated protein
glyoxalase I
glia maturation
factor, beta
guanine nucleotide
binding protein (G
protein), alpha 11
(Gq class)
guanine nucleotide
binding proteinlike 1
golgi autoantigen,
golgin subfamily a,
1
growth factor
receptor-bound
protein 2
general
transcription factor
IIF, polypeptide 2,
30kDa

GTF2H1

GTF3C4

H2AFY
H3F3A
HADHB

HERC4
HFE
HIP2
HIST2H2
BE
HLADPA1
HMGA1
HMGN4
HNRPDL

HTATSF
1
HUS1
HYPK
IDH3A

	
  

general
transcription factor
IIH, polypeptide 1,
62kDa
general
transcription factor
IIIC, polypeptide
4, 90kDa
H2A histone
family, member Y
H3 histone, family
3A
hydroxyacylCoenzyme A
dehydrogenase/3ketoacylCoenzyme A
thiolase/enoylCoenzyme A
hydratase
(trifunctional
protein), beta
subunit
hect domain and
RLD 4
hemochromatosis

IDS
IFIT3

IFNAR1
IGFBP3
IL27RA
IMPDH2
IQCB1
IRAK4
ITCH

huntingtin
interacting protein
2
histone 2, H2be

ITM2B

major
histocompatibility
complex, class II,
DP alpha 1
high mobility
group AT-hook 1
high mobility
group nucleosomal
binding domain 4
heterogeneous
nuclear
ribonucleoprotein
D-like
HIV TAT specific
factor 1
HUS1 checkpoint
homolog (S.
pombe)
Huntingtin
interacting protein
K
isocitrate
dehydrogenase 3
(NAD+) alpha

JMJD4

ITPK1

KATNB1
KCNS3

KCTD2

KIAA049
4
KIAA049
5
KIAA065
2
KIAA089
2
KIAA097
4
KIAA112
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iduronate 2sulfatase (Hunter
syndrome)
interferon-induced
protein with
tetratricopeptide
repeats 3
interferon (alpha,
beta and omega)
receptor 1
insulin-like growth
factor binding
protein 3
interleukin 27
receptor, alpha
IMP (inosine
monophosphate)
dehydrogenase 2
IQ motif
containing B1
interleukin-1
receptor-associated
kinase 4
itchy homolog E3
ubiquitin protein
ligase (mouse)
integral membrane
protein 2B
inositol 1,3,4triphosphate 5/6
kinase
jumonji domain
containing 4
katanin p80 (WD
repeat containing)
subunit B 1
potassium voltagegated channel,
delayed-rectifier,
subfamily S,
member 3
potassium channel
tetramerisation
domain containing
2
KIAA0494
KIAA0495
KIAA0652
KIAA0892
KIAA0974 mRNA
KIAA1128

8
KIAA201
0
KLHL12
KRIT1
LAP3
LBH
LDLRAP
1
LEPR
LEPROT
LEPROT
L1
LIF

LMF2
LOC1274
06
LOC1453
87
LOC6392
0
LOC9224
9
LPXN
M6PR
MAEA
MAP2K3
MAP3K7
MBD4

	
  

KIAA2010

MCM4

kelch-like 12
(Drosophila)
KRIT1, ankyrin
repeat containing
leucine
aminopeptidase 3
limb bud and heart
development
homolog (mouse)
low density
lipoprotein
receptor adaptor
protein 1
leptin receptor

MDH2

MELK
MGAT2

leptin receptor
overlapping
transcript
leptin receptor
overlapping
transcript-like 1
leukemia
inhibitory factor
(cholinergic
differentiation
factor)
lipase maturation
factor 2
similar to laminin
receptor 1
(ribosomal protein
SA)
LOC145387

MGC127
60
MGC326
2
MIPEP
MKRN1
MMP24

MNS1
MON1B

transposon-derived
Buster3
transposase-like
hypothetical
protein LOC92249
leupaxin

MOSPD1

mannose-6phosphate receptor
(cation dependent)
macrophage
erythroblast
attacher
mitogen-activated
protein kinase
kinase 3
mitogen-activated
protein kinase
kinase kinase 7
methyl-CpG

MSRB2

MRP63

MSTO1
MTCH1
MTHFD2

116	
  

binding domain
protein 4
MCM4
minichromosome
maintenance
deficient 4 (S.
cerevisiae)
malate
dehydrogenase 2,
NAD
(mitochondrial)
maternal
embryonic leucine
zipper kinase
mannosyl (alpha1,6-)-glycoprotein
beta-1,2-Nacetylglucosaminyl
transferase
hypothetical
protein
MGC12760
hypothetical
protein MGC3262
mitochondrial
intermediate
peptidase
makorin, ring
finger protein, 1
matrix
metalloproteinase
24 (membraneinserted)
meiosis-specific
nuclear structural 1
MON1 homolog B
(yeast)
motile sperm
domain containing
1
mitochondrial
ribosomal protein
63
methionine
sulfoxide reductase
B2
misato homolog 1
(Drosophila)
mitochondrial
carrier homolog 1
(C. elegans)
methylenetetrahydr
ofolate
dehydrogenase
(NADP+
dependent) 2,

methenyltetrahydro
folate
cyclohydrolase

MTUS1
MUM1
MXD4
NDRG3
NET1
NFIC

NFIL3
NFKBIA

NFYA
NR2C1
NR2C2
NR2F6
NRF1
NUDT13

OSR2
PACS2

PAICS

mitochondrial
tumor suppressor 1
melanoma
associated antigen
(mutated) 1
MAX dimerization
protein 4
NDRG family
member 3
neuroepithelial cell
transforming gene
1
nuclear factor I/C
(CCAAT-binding
transcription
factor)
nuclear factor,
interleukin 3
regulated
nuclear factor of
kappa light
polypeptide gene
enhancer in B-cells
inhibitor, alpha
nuclear
transcription factor
Y, alpha
nuclear receptor
subfamily 2, group
C, member 1
nuclear receptor
subfamily 2, group
C, member 2
nuclear receptor
subfamily 2, group
F, member 6
nuclear respiratory
factor 1
nudix (nucleoside
diphosphate linked
moiety X)-type
motif 13
odd-skipped
related 2
(Drosophila)
phosphofurin
acidic cluster
sorting protein 2

PAK4
PAM
PARP16
PARVA
PBLD

PDCD4

PDE8A
PDGFA
PDLIM5
PHLDA1

PIGO
PIP5K2A

PIP5K2B

PKP3
PLA2G6

PLK4
POLR2D
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phosphoribosylami
noimidazole
carboxylase,
phosphoribosylami
noimidazole
succinocarboxamid
e synthetase
p21(CDKN1A)activated kinase 4
peptidylglycine
alpha-amidating
monooxygenase
poly (ADP-ribose)
polymerase family,
member 16
parvin, alpha
phenazine
biosynthesis-like
protein domain
containing
programmed cell
death 4 (neoplastic
transformation
inhibitor)
phosphodiesterase
8A
platelet-derived
growth factor alpha
polypeptide
PDZ and LIM
domain 5
pleckstrin
homology-like
domain, family A,
member 1
phosphatidylinosit
ol glycan, class O
phosphatidylinosit
ol-4-phosphate 5kinase, type II,
alpha
phosphatidylinosit
ol-4-phosphate 5kinase, type II,
beta
plakophilin 3
phospholipase A2,
group VI
(cytosolic,
calciumindependent)
polo-like kinase 4
(Drosophila)
polymerase (RNA)
II (DNA directed)

polypeptide D
PPCS
PPIC
PPM1G

PPP2CB

PRDM2
PRDX3
PREI3
PRKACB
PRPS1
PRR14
PRSS3
PSMC3

PSMC3I
P
PSMD14

PSPC1
PSTPIP2

PTDSS1

	
  

PTEN

phosphopantotheno
ylcysteine
synthetase
peptidylprolyl
isomerase C
(cyclophilin C)
protein
phosphatase 1G
(formerly 2C),
magnesiumdependent, gamma
isoform
protein
phosphatase 2
(formerly 2A),
catalytic subunit,
beta isoform
PR domain
containing 2, with
ZNF domain
peroxiredoxin 3

PTENP1

PTN

PTTG1IP
PUS3
PYGO1
RAB11A

preimplantation
protein 3
protein kinase,
cAMP-dependent,
catalytic, beta
phosphoribosyl
pyrophosphate
synthetase 1
proline rich 14

RAB27B
RAB8A
RABIF

protease, serine, 3
(mesotrypsin)
proteasome
(prosome,
macropain) 26S
subunit, ATPase, 3
PSMC3 interacting
protein
proteasome
(prosome,
macropain) 26S
subunit, nonATPase, 14
paraspeckle
component 1
proline-serinethreonine
phosphatase
interacting protein
2
phosphatidylserine
synthase 1

RAD51L
3
RAP1GD
S1
RBMS3

RCC1
REXO2

RGL2

RGS10
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phosphatase and
tensin homolog
(mutated in
multiple advanced
cancers 1)
phosphatase and
tensin homolog
(mutated in
multiple advanced
cancers 1),
pseudogene 1
pleiotrophin
(heparin binding
growth factor 8,
neurite growthpromoting factor 1)
pituitary tumortransforming 1
interacting protein
pseudouridylate
synthase 3
pygopus homolog
1 (Drosophila)
RAB11A, member
RAS oncogene
family
RAB27B, member
RAS oncogene
family
RAB8A, member
RAS oncogene
family
RAB interacting
factor
RAD51-like 3 (S.
cerevisiae)
RAP1, GTP-GDP
dissociation
stimulator 1
RNA binding
motif, single
stranded
interacting protein
regulator of
chromosome
condensation 1
REX2, RNA
exonuclease 2
homolog (S.
cerevisiae)
ral guanine
nucleotide
dissociation
stimulator-like 2
regulator of Gprotein signalling

10
RINT1
RIOK3
RIPK1

RNF11
RNF13
RNF139
RNF216
RNF24
RNF4
RNF44
RP4692D3.1
RPL12
RPL13A
RPL15
RPL18A
RPL21
RPL22
RPL28
RPL31
RPL38
RPL5
RPN1
RPS12
RPS19
RPS21
RPS27A

	
  

RPS28

RAD50 interactor
1
RIO kinase 3
(yeast)
receptor
(TNFRSF)interacting serinethreonine kinase 1
ring finger protein
11
ring finger protein
13
ring finger protein
139
ring finger protein
216
ring finger protein
24
ring finger protein
4
ring finger protein
44
hypothetical
protein
LOC728621
ribosomal protein
L12
ribosomal protein
L13a
ribosomal protein
L15
ribosomal protein
L18a
ribosomal protein
L21
ribosomal protein
L22
ribosomal protein
L28
ribosomal protein
L31
ribosomal protein
L38
ribosomal protein
L5
ribophorin I

RPS6
RTF1

SAP18
SC4MOL
SCAMP1
SCAMP5
SCML1
SCRN3
SCYE1

SCYL3
SDC2

SDC4
SDFR1
SEC11L1
SEMA4F

ribosomal protein
S12
ribosomal protein
S19
ribosomal protein
S21
ribosomal protein
S27a
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ribosomal protein
S28
ribosomal protein
S6
Rtf1, Paf1/RNA
polymerase II
complex
component,
homolog (S.
cerevisiae)
sin3-associated
polypeptide,
18kDa
sterol-C4-methyl
oxidase-like
secretory carrier
membrane protein
1
secretory carrier
membrane protein
5
sex comb on
midleg-like 1
(Drosophila)
secernin 3
small inducible
cytokine subfamily
E, member 1
(endothelial
monocyteactivating)
SCY1-like 3 (S.
cerevisiae)
syndecan 2
(heparan sulfate
proteoglycan 1,
cell surfaceassociated,
fibroglycan)
syndecan 4
(amphiglycan,
ryudocan)
stromal cell
derived factor
receptor 1
SEC11-like 1 (S.
cerevisiae)
sema domain,
immunoglobulin
domain (Ig),
transmembrane
domain (TM) and
short cytoplasmic
domain,
(semaphorin) 4F

SEPT11

septin 11

SERINC
3
SF3A1

serine incorporator
3
splicing factor 3a,
subunit 1, 120kDa
stratifin

SFN

SSRP1

splicing factor,
arginine/serine-rich
14
sideroflexin 3

ST13

STC1

SMS

short stature
homeobox 2
sirtuin (silent
mating type
information
regulation 2
homolog) 5 (S.
cerevisiae)
sine oculis
homeobox
homolog 1
(Drosophila)
S-phase kinaseassociated protein
1A (p19A)
solute carrier
family 25, member
37
solute carrier
family 26, member
4
solute carrier
family 35, member
E1
SMAD, mothers
against DPP
homolog 5
(Drosophila)
SWI/SNF related,
matrix associated,
actin dependent
regulator of
chromatin,
subfamily d,
member 3
spermine synthase

SNN

stannin

SOD2

superoxide
dismutase 2,
mitochondrial
SP110 nuclear
body protein
Sp2 transcription
factor

SFRS14
SFXN3
SHOX2
SIRT5

SIX1

SKP1A
SLC25A
37
SLC26A
4
SLC35E1
SMAD5

SMARC
D3

SP110
SP2

	
  

SPATA2
L
SRR

STCH

structure specific
recognition protein
1
suppression of
tumorigenicity 13
(colon carcinoma)
(Hsp70 interacting
protein)
stanniocalcin 1

STX12

stress 70 protein
chaperone,
microsomeassociated, 60kDa
serine/threonine
kinase 24 (STE20
homolog, yeast)
stomatin (EPB72)like 1
syntaxin 12

STX6

syntaxin 6

STX7

syntaxin 7

STK24
STOML1

STYK1
SVIL
SYBL1
TACSTD
2
TAF1A

TBXA2R
TDP1
TERF1

TES
TEX261
TGFBR2
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spermatogenesis
associated 2-like
serine racemase

serine/threonine/tyr
osine kinase 1
supervillin
synaptobrevin-like
1
tumor-associated
calcium signal
transducer 2
TATA box binding
protein (TBP)associated factor,
RNA polymerase I,
A, 48kDa
thromboxane A2
receptor
tyrosyl-DNA
phosphodiesterase
1
telomeric repeat
binding factor
(NIMAinteracting) 1
testis derived
transcript (3 LIM
domains)
testis expressed
sequence 261
transforming
growth factor, beta
receptor II

(70/80kDa)
TGIF2
THAP1

TIMM44

TIMP3

TM7SF1

TMEFF1

TNFRSF
1A
TOB1
TOM1L1
TPI1
TPK1
TPM1
TTC4
TULP3
TWISTN
B
TXK
TXNDC

	
  

UBE2NL

TGFB-induced
factor 2 (TALE
family homeobox)
THAP domain
containing,
apoptosis
associated protein
1
translocase of inner
mitochondrial
membrane 44
homolog (yeast)
TIMP
metallopeptidase
inhibitor 3 (Sorsby
fundus dystrophy,
pseudoinflammator
y)
transmembrane 7
superfamily
member 1
(upregulated in
kidney)
transmembrane
protein with EGFlike and two
follistatin-like
domains 1
tumor necrosis
factor receptor
superfamily,
member 1A
transducer of
ERBB2, 1
target of myb1-like
1 (chicken)
triosephosphate
isomerase 1
thiamin
pyrophosphokinase
1
tropomyosin 1
(alpha)
tetratricopeptide
repeat domain 4
tubby like protein
3
TWIST neighbor

XPO6

ubiquitinconjugating
enzyme E2N-like
ubiquitin-fold
modifier 1
ubiquitin
interaction motif
containing 1
ubiquinolcytochrome c
reductase binding
protein
vesicle-associated
membrane protein
3 (cellubrevin)
VAMP (vesicleassociated
membrane
protein)-associated
protein A, 33kDa
vacuolar protein
sorting 24 (yeast)
WD repeat domain
46
WD repeat domain
48
exportin 6

XPO7

exportin 7

YRDC

yrdC domain
containing (E.coli)
tyrosine 3monooxygenase/tr
yptophan 5monooxygenase
activation protein,
zeta polypeptide
zinc finger, BEDtype containing 1
zinc finger, CCHC
domain containing
10
zinc finger, CCHC
domain containing
4
zinc finger, AN1type domain 1
zinc finger protein
37 homolog
(mouse)
zinc finger protein
177
zinc finger protein
227
zinc finger protein
230

UFM1
UIMC1
UQCRB

VAMP3
VAPA

VPS24
WDR46
WDR48

YWHAZ

ZBED1
ZCCHC1
0
ZCCHC4
ZFAND1
ZFP37
ZNF177

TXK tyrosine
kinase
thioredoxin
domain containing

ZNF227
ZNF230
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ZNF306
ZNF330
ZNF505
ZNF557

	
  

zinc finger protein
306
zinc finger protein
330
zinc finger protein
505
zinc finger protein
557

ZNF675
ZWINT
ZXDC

122	
  

zinc finger protein
675
ZW10 interactor
ZXD family zinc
finger C

